

# Munir Pirmohamed

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6001092/publications.pdf>

Version: 2024-02-01

670  
papers

42,014  
citations

2795

94  
h-index

3997

176  
g-index

705  
all docs

705  
docs citations

705  
times ranked

37405  
citing authors

#	ARTICLE	IF	CITATIONS
1	Drug repurposing: progress, challenges and recommendations. <i>Nature Reviews Drug Discovery</i> , 2019, 18, 41-58.	21.5	2,689
2	Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. <i>BMJ: British Medical Journal</i> , 2004, 329, 15-19.	2.4	2,430
3	Phase I Clinical Trial of Oral Curcumin. <i>Clinical Cancer Research</i> , 2004, 10, 6847-6854.	3.2	1,097
4	HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. <i>Nature Genetics</i> , 2009, 41, 816-819.	9.4	950
5	HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans. <i>New England Journal of Medicine</i> , 2011, 364, 1134-1143.	13.9	815
6	A Randomized Trial of Genotype-Guided Dosing of Warfarin. <i>New England Journal of Medicine</i> , 2013, 369, 2294-2303.	13.9	735
7	Emergence and global spread of epidemic healthcare-associated <i>Clostridium difficile</i> . <i>Nature Genetics</i> , 2013, 45, 109-113.	9.4	669
8	Active transport of imatinib into and out of cells: implications for drug resistance. <i>Blood</i> , 2004, 104, 3739-3745.	0.6	598
9	Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 625-629.	2.3	571
10	Adverse Drug Reactions in Hospital In-Patients: A Prospective Analysis of 3695 Patient-Episodes. <i>PLoS ONE</i> , 2009, 4, e4439.	1.1	527
11	Which drugs cause preventable admissions to hospital? A systematic review. <i>British Journal of Clinical Pharmacology</i> , 2007, 63, 136-147.	1.1	499
12	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 397-404.	2.3	479
13	THE ROLE OF METABOLIC ACTIVATION IN DRUG-INDUCED HEPATOTOXICITY. <i>Annual Review of Pharmacology and Toxicology</i> , 2005, 45, 177-202.	4.2	422
14	Susceptibility to Amoxicillin-Clavulanate-Induced Liver Injury Is Influenced by Multiple HLA Class I and II Alleles. <i>Gastroenterology</i> , 2011, 141, 338-347.	0.6	412
15	Fortnightly review: Adverse drug reactions. <i>BMJ: British Medical Journal</i> , 1998, 316, 1295-1298.	2.4	363
16	Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2011, 13, 1-10.	2.9	350
17	Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. <i>Blood</i> , 2010, 115, 3827-3834.	0.6	331
18	HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. <i>Pharmacogenomics</i> , 2006, 7, 813-818.	0.6	310

#	ARTICLE	IF	CITATIONS
19	How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?. <i>British Journal of Pharmacology</i> , 2011, 163, 675-693.	2.7	306
20	Genetic susceptibility to adverse drug reactions. <i>Trends in Pharmacological Sciences</i> , 2001, 22, 298-305.	4.0	294
21	Pharmacogenetics of warfarin: current status and future challenges. <i>Pharmacogenomics Journal</i> , 2007, 7, 99-111.	0.9	290
22	Warfarin: almost 60 years old and still causing problems. <i>British Journal of Clinical Pharmacology</i> , 2006, 62, 509-511.	1.1	283
23	Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. <i>Pharmacogenetics and Genomics</i> , 2004, 14, 335-342.	5.7	274
24	Role of Drug Disposition in Drug Hypersensitivity: A Chemical, Molecular, and Clinical Perspective. <i>Chemical Research in Toxicology</i> , 1998, 11, 969-988.	1.7	260
25	Expression of the Uptake Drug Transporter hOCT1 is an Important Clinical Determinant of the Response to Imatinib in Chronic Myeloid Leukemia. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 258-264.	2.3	253
26	ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. <i>Pharmacogenomics Journal</i> , 2007, 7, 154-179.	0.9	247
27	Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 341-358.	2.3	240
28	Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Carbamazepine Dosing. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 324-328.	2.3	237
29	Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. <i>Hepatology</i> , 2013, 57, 727-739.	3.6	212
30	Hypersensitivity Reactions to Carbamazepine: Characterization of the Specificity, Phenotype, and Cytokine Profile of Drug-Specific T Cell Clones. <i>Molecular Pharmacology</i> , 2003, 63, 732-741.	1.0	211
31	Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 574-581.	2.3	211
32	Management of allergy to penicillins and other beta-lactams. <i>Clinical and Experimental Allergy</i> , 2015, 45, 300-327.	1.4	210
33	Recognition of Sulfamethoxazole and Its Reactive Metabolites by Drug-Specific CD4+ T Cells from Allergic Individuals. <i>Journal of Immunology</i> , 2000, 164, 6647-6654.	0.4	206
34	Integration of Genetic, Clinical, and INR Data to Refine Warfarin Dosing. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 87, 572-578.	2.3	202
35	Characterization of drug-specific T cells in lamotrigine hypersensitivity. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 111, 1393-1403.	1.5	198
36	hOCT 1 and resistance to imatinib. <i>Blood</i> , 2005, 106, 1133-1134.	0.6	196

#	ARTICLE	IF	CITATIONS
37	Improved Glycaemia Correlates with Liver Fat Reduction in Obese, Type 2 Diabetes, Patients Given Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists. <i>PLoS ONE</i> , 2012, 7, e50117.	1.1	191
38	Antibiotic Allergy. <i>New England Journal of Medicine</i> , 2006, 354, 601-609.	13.9	183
39	Review article: cellular and molecular mechanisms of NSAID-induced peptic ulcers. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 517-531.	1.9	182
40	Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 91, 734-738.	2.3	174
41	Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. <i>Gastroenterology</i> , 2017, 152, 1078-1089.	0.6	174
42	Phenotype Standardization for Statin-Induced Myotoxicity. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 470-476.	2.3	166
43	Metabolism and bioactivation of clozapine by human liver in vitro. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1995, 272, 984-90.	1.3	164
44	Development and Inter-Rater Reliability of the Liverpool Adverse Drug Reaction Causality Assessment Tool. <i>PLoS ONE</i> , 2011, 6, e28096.	1.1	157
45	Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles. <i>Nature Communications</i> , 2014, 5, 4757.	5.8	153
46	Controversies in drug allergy: Testing for delayed reactions. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 66-73.	1.5	144
47	Characterisation of the toxic metabolite(s) of naphthalene. <i>Toxicology</i> , 1996, 114, 233-242.	2.0	143
48	Influence of CYP2C9 and VKORC1 on Patient Response to Warfarin: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2012, 7, e44064.	1.1	142
49	TNF promoter region gene polymorphisms in carbamazepine-hypersensitive patients. <i>Neurology</i> , 2001, 56, 890-896.	1.5	138
50	Glucuronidation of Dihydroartemisinin in Vivo and by Human Liver Microsomes and Expressed UDP-Glucuronosyltransferases. <i>Drug Metabolism and Disposition</i> , 2002, 30, 1005-1012.	1.7	138
51	Challenges and approaches for the development of safer immunomodulatory biologics. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 306-324.	21.5	138
52	Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. <i>Journal of Hepatology</i> , 2010, 53, 1049-1053.	1.8	137
53	Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. <i>BMJ: British Medical Journal</i> , 2011, 343, d6333-d6333.	2.4	137
54	HLA Genotype and Carbamazepine-Induced Cutaneous Adverse Drug Reactions: A Systematic Review. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 757-765.	2.3	137

#	ARTICLE	IF	CITATIONS
55	Pragmatic randomised trials using routine electronic health records: putting them to the test. <i>BMJ: British Medical Journal</i> , 2012, 344, e55-e55.	2.4	136
56	Attitudes and knowledge of hospital pharmacists to adverse drug reaction reporting. <i>British Journal of Clinical Pharmacology</i> , 2001, 51, 81-86.	1.1	134
57	SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 38-69.	2.0	134
58	The danger hypothesisâ€™ potential role in idiosyncratic drug reactions. <i>Toxicology</i> , 2002, 181-182, 55-63.	2.0	133
59	Cytochrome P450 enzyme polymorphisms and adverse drug reactions. <i>Toxicology</i> , 2003, 192, 23-32.	2.0	132
60	Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. <i>Pharmacogenomics</i> , 2009, 10, 1687-1695.	0.6	131
61	The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. , 1995, 68, 385-424.		130
62	Covalent Binding of the Nitroso Metabolite of Sulfamethoxazole Leads to Toxicity and Major Histocompatibility Complex-Restricted Antigen Presentation. <i>Molecular Pharmacology</i> , 2002, 62, 628-637.	1.0	129
63	Pharmacogenetics and pharmacogenomics. <i>British Journal of Clinical Pharmacology</i> , 2001, 52, 345-347.	1.1	128
64	Personalized Pharmacogenomics: Predicting Efficacy and Adverse Drug Reactions. <i>Annual Review of Genomics and Human Genetics</i> , 2014, 15, 349-370.	2.5	128
65	Immunological Principles of Adverse Drug Reactions. <i>Drug Safety</i> , 2000, 23, 483-507.	1.4	127
66	Drug-grapefruit juice interactions. <i>BMJ, The</i> , 2013, 346, f1-f1.	3.0	127
67	Cellular disposition of sulphamethoxazole and its metabolites: implications for hypersensitivity. <i>British Journal of Pharmacology</i> , 1999, 126, 1393-1407.	2.7	126
68	SLCO1B1 Genetic Variant Associated With Statin-Induced Myopathy: A Proof-of-Concept Study Using the Clinical Practice Research Datalink. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 695-701.	2.3	124
69	Carbamazepine is not a substrate for P-glycoprotein. <i>British Journal of Clinical Pharmacology</i> , 2001, 51, 345-349.	1.1	123
70	Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 Update. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 499-500.	2.3	123
71	Advances in molecular toxicologyâ€™towards understanding idiosyncratic drug toxicity. <i>Toxicology</i> , 2000, 153, 39-60.	2.0	122
72	Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components. <i>Journal of Clinical Medicine</i> , 2020, 9, 22.	1.0	122

#	ARTICLE	IF	CITATIONS
73	Metabolic activation in drug allergies. <i>Toxicology</i> , 2001, 158, 11-23.	2.0	121
74	Activation of T cells by carbamazepine and carbamazepine metabolites. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 118, 233-241.	1.5	121
75	Induction of Metabolism-Dependent and -Independent Neutrophil Apoptosis by Clozapine. <i>Molecular Pharmacology</i> , 2000, 58, 207-216.	1.0	120
76	Transport of gabapentin by LAT1 (SLC7A5). <i>Biochemical Pharmacology</i> , 2013, 85, 1672-1683.	2.0	120
77	A Review of the Important Role of CYP2D6 in Pharmacogenomics. <i>Genes</i> , 2020, 11, 1295.	1.0	120
78	Idiosyncratic drug reactions: a mechanistic evaluation of risk factors.. <i>British Journal of Clinical Pharmacology</i> , 1992, 34, 377-395.	1.1	116
79	Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptentation and T-cell proliferation in vivo. <i>British Journal of Pharmacology</i> , 2001, 133, 295-305.	2.7	115
80	Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. <i>Blood</i> , 2008, 112, 3348-3354.	0.6	115
81	The opportunities and challenges of pragmatic point-of-care randomised trials using routinely collected electronic records: evaluations of two exemplar trials. <i>Health Technology Assessment</i> , 2014, 18, 1-146.	1.3	114
82	Possible interaction between warfarin and cranberry juice. <i>BMJ: British Medical Journal</i> , 2003, 327, 1454-1454.	2.4	112
83	Sulfamethoxazole and Its Metabolite Nitroso Sulfamethoxazole Stimulate Dendritic Cell Costimulatory Signaling. <i>Journal of Immunology</i> , 2007, 178, 5533-5542.	0.4	111
84	A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions. <i>Pharmacoeconomics</i> , 2016, 34, 771-793.	1.7	111
85	A method for the rapid depletion of albumin and immunoglobulin from human plasma. <i>Proteomics</i> , 2004, 4, 3107-3111.	1.3	109
86	Metabolism of Lamotrigine to a Reactive Arene Oxide Intermediate. <i>Chemical Research in Toxicology</i> , 2000, 13, 1075-1081.	1.7	107
87	Enzyme-Induction Dependent Bioactivation of Troglitazone and Troglitazone Quinone In Vivo. <i>Chemical Research in Toxicology</i> , 2001, 14, 965-974.	1.7	107
88	Association analysis of drug metabolizing enzyme gene polymorphisms in HIV-positive patients with co-trimoxazole hypersensitivity. <i>Pharmacogenetics and Genomics</i> , 2000, 10, 705-713.	5.7	106
89	Generation and characterization of antigen-specific CD4+, CD8+, and CD4+CD8+ T-cell clones from patients with carbamazepine hypersensitivity. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 119, 973-981.	1.5	104
90	Social media and pharmacovigilance: A review of the opportunities and challenges. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 910-920.	1.1	103

#	ARTICLE	IF	CITATIONS
91	Genetic Variants of ABCC10, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction. <i>Journal of Infectious Diseases</i> , 2011, 204, 145-153.	1.9	102
92	Zoonotic Transfer of <i>Clostridium difficile</i> Harboring Antimicrobial Resistance between Farm Animals and Humans. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	1.8	102
93	TNF- $\alpha$ promoter region gene polymorphisms in HIV-positive patients with lipodystrophy. <i>Aids</i> , 2002, 16, 2013-2018.	1.0	101
94	Characterisation of flucloxacillin and 5 $\alpha$ -hydroxymethyl flucloxacillin haptenated HSA <i>in vitro</i> and <i>in vivo</i> . <i>Proteomics - Clinical Applications</i> , 2009, 3, 720-729.	0.8	101
95	Mass Spectrometric Characterization of Circulating and Functional Antigens Derived from Piperacillin in Patients with Cystic Fibrosis. <i>Journal of Immunology</i> , 2011, 187, 200-211.	0.4	101
96	Association of Human Leukocyte Antigen Alleles and Nevirapine Hypersensitivity in a Malawian HIV-Infected Population. <i>Clinical Infectious Diseases</i> , 2013, 56, 1330-1339.	2.9	100
97	Effect of topiramate on acid-base balance: extent, mechanism and effects. <i>British Journal of Clinical Pharmacology</i> , 2009, 68, 655-661.	1.1	99
98	Emergency readmissions to hospital due to adverse drug reactions within 1 year of the index admission. <i>British Journal of Clinical Pharmacology</i> , 2010, 70, 749-755.	1.1	99
99	Phenotype Standardization for Immune-Mediated Drug-Induced Skin Injury. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 89, 896-901.	2.3	99
100	Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. <i>Pharmacogenomics Journal</i> , 2011, 11, 1-14.	0.9	99
101	Immunogenicity to Biologics: Mechanisms, Prediction and Reduction. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2012, 60, 331-344.	1.0	99
102	Risk stratification after paracetamol overdose using mechanistic biomarkers: results from two prospective cohort studies. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 104-113.	3.7	99
103	Aminoglycoside-induced nephrotoxicity in children. <i>Pediatric Nephrology</i> , 2017, 32, 2015-2025.	0.9	97
104	A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury. <i>Gastroenterology</i> , 2019, 156, 1707-1716.e2.	0.6	97
105	Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. <i>Leukemia</i> , 2009, 23, 1999-2006.	3.3	95
106	Short-term exercise training improves body composition and hyperlipidaemia in HIV-positive individuals with lipodystrophy. <i>Aids</i> , 2001, 15, 2049-2051.	1.0	95
107	Investigation of toxic metabolites during drug development. <i>Toxicology and Applied Pharmacology</i> , 2005, 207, 425-434.	1.3	94
108	Off-label and unlicensed medicine use and adverse drug reactions in children: a narrative review of the literature. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 21-28.	0.8	94

#	ARTICLE	IF	CITATIONS
109	HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 648-660.	1.3	91
110	Aspirin resistance: Effect of clinical, biochemical and genetic factors. , 2011, 130, 213-225.		90
111	Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsy. <i>Journal of Clinical Investigation</i> , 2017, 127, 2118-2132.	3.9	90
112	An investigation of the formation of cytotoxic, protein-reactive and stable metabolites from carbamazepine in vitro. <i>Biochemical Pharmacology</i> , 1992, 43, 1675-1682.	2.0	89
113	Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine. <i>Archives of Dermatology</i> , 1994, 130, 598-604.	1.7	89
114	Adverse drug reactions and off-label and unlicensed medicines in children: a nested case-control study of inpatients in a pediatric hospital. <i>BMC Medicine</i> , 2013, 11, 238.	2.3	88
115	Genetic analysis of microsomal epoxide hydrolase in patients with carbamazepine hypersensitivity. <i>Biochemical Pharmacology</i> , 1995, 50, 1353-1359.	2.0	87
116	Relevance of induction of human drug-metabolizing enzymes: pharmacological and toxicological implications. <i>British Journal of Clinical Pharmacology</i> , 1996, 41, 477-491.	1.1	86
117	Genetic factors in the predisposition to drug-induced hypersensitivity reactions. <i>AAPS Journal</i> , 2006, 8, E20-E26.	2.2	84
118	Interaction of metoprolol and fluoxetine. <i>Lancet, The</i> , 1993, 341, 967-968.	6.3	83
119	Characterization of amoxicillin- and clavulanic acid-specific T cells in patients with amoxicillin-clavulanate-induced liver injury. <i>Hepatology</i> , 2015, 62, 887-899.	3.6	83
120	Mechanism of Clozapine-Induced Agranulocytosis. <i>CNS Drugs</i> , 1997, 7, 139-158.	2.7	82
121	Adverse Drug Reactions in Hospitals: A Narrative Review. <i>Current Drug Safety</i> , 2007, 2, 79-87.	0.3	82
122	Adverse drug reactions and off-label and unlicensed medicines in children: a prospective cohort study of unplanned admissions to a paediatric hospital. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 545-553.	1.1	82
123	Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: possible role in agranulocytosis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1997, 283, 1375-82.	1.3	82
124	Idiosyncratic Drug Reactions. <i>Clinical Pharmacokinetics</i> , 1996, 31, 215-230.	1.6	81
125	Expression of cytochrome P4502E1 in human liver: assessment by mRNA, genotype and phenotype. <i>Pharmacogenetics and Genomics</i> , 1998, 8, 411-421.	5.7	81
126	Pharmacovigilance in developing countries. <i>BMJ: British Medical Journal</i> , 2007, 335, 462-462.	2.4	81



#	ARTICLE	IF	CITATIONS
127	Reporting of adverse drug reactions by nurses. <i>Lancet, The</i> , 2003, 361, 1347-1348.	6.3	80
128	Pharmacogenetics: past, present and future. <i>Drug Discovery Today</i> , 2011, 16, 852-861.	3.2	80
129	New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 236-244.	1.5	80
130	Childhood asthma exacerbations and the Arg16 Î²2-receptor polymorphism: A meta-analysis stratified by treatment. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 107-113.e5.	1.5	80
131	Metabolism-Dependent Neutrophil Cytotoxicity of Amodiaquine: A Comparison with Pyronaridine and Related Antimalarial Drugs. <i>Chemical Research in Toxicology</i> , 1998, 11, 1586-1595.	1.7	79
132	The burden of alcohol misuse on an inner-city general hospital. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2000, 93, 291-295.	0.2	78
133	Direct Evidence for the Formation of Diastereoisomeric Benzylpenicilloyl Haptens from Benzylpenicillin and Benzylpenicillic Acid in Patients. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 338, 841-849.	1.3	78
134	Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study. <i>Oral Diseases</i> , 2017, 23, 477-483.	1.5	78
135	The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1995, 275, 1463-75.	1.3	78
136	HIV and drug allergy. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2001, 1, 311-316.	1.1	77
137	Incidence, characteristics and risk factors of adverse drug reactions in hospitalized children - a prospective observational cohort study of 6,601 admissions. <i>BMC Medicine</i> , 2013, 11, 237.	2.3	77
138	Genetic polymorphism of cytochrome P4502E1 and risk of alcoholic liver disease in Caucasians. <i>Pharmacogenetics and Genomics</i> , 1995, 5, 351-357.	5.7	74
139	An investigation of the formation of cytotoxic, genotoxic, protein-reactive and stable metabolites from naphthalene by human liver microsomes. <i>Biochemical Pharmacology</i> , 1993, 46, 1529-1538.	2.0	73
140	Hypersensitivity reactions to HIV therapy. <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 659-671.	1.1	73
141	Lamotrigine is a substrate for OCT1 in brain endothelial cells. <i>Biochemical Pharmacology</i> , 2012, 83, 805-814.	2.0	73
142	Characterization of the Antigen Specificity of T-Cell Clones from Piperacillin-Hypersensitive Patients with Cystic Fibrosis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 341, 597-610.	1.3	72
143	Intravenous therapy. <i>Postgraduate Medical Journal</i> , 2004, 80, 1-6.	0.9	71
144	Personalized medicine approaches in epilepsy. <i>Journal of Internal Medicine</i> , 2015, 277, 218-234.	2.7	71

#	ARTICLE	IF	CITATIONS
145	Genome-Based Infection Tracking Reveals Dynamics of <i>Clostridium difficile</i> Transmission and Disease Recurrence. <i>Clinical Infectious Diseases</i> , 2016, 62, 746-752.	2.9	71
146	The population pharmacokinetics of <i>R</i> - and <i>S</i> -warfarin: effect of genetic and clinical factors. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 66-76.	1.1	70
147	Oral anticoagulation: a critique of recent advances and controversies. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 153-163.	4.0	70
148	Adverse Drug Reactions Causing Admission to a Paediatric Hospital. <i>PLoS ONE</i> , 2012, 7, e50127.	1.1	70
149	The Role of Active Metabolites in Drug Toxicity. <i>Drug Safety</i> , 1994, 11, 114-144.	1.4	69
150	Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver. <i>British Journal of Clinical Pharmacology</i> , 2005, 59, 365-370.	1.1	69
151	Mechanism-Based Urinary Biomarkers to Identify the Potential for Aminoglycoside-Induced Nephrotoxicity in Premature Neonates: A Proof-of-Concept Study. <i>PLoS ONE</i> , 2012, 7, e43809.	1.1	69
152	Characterization of Sulfamethoxazole and Sulfamethoxazole Metabolite-Specific T-Cell Responses in Animals and Humans. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 306, 229-237.	1.3	68
153	Clinical factors and ABCB1 polymorphisms in prediction of antiepileptic drug response: a prospective cohort study. <i>Lancet Neurology</i> , The, 2006, 5, 668-676.	4.9	68
154	Synthesis and reactions of nitroso sulphamethoxazole with biological nucleophiles: Implications for immune mediated toxicity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1996, 6, 1511-1516.	1.0	67
155	A Proposal for an Individualized Pharmacogenetics-Based Warfarin Initiation Dose Regimen for Patients Commencing Anticoagulation Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 701-706.	2.3	67
156	The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia. <i>Blood</i> , 2013, 121, 628-637.	0.6	66
157	Physiological, pharmacological and toxicological considerations of drug-induced structural cardiac injury. <i>British Journal of Pharmacology</i> , 2015, 172, 957-974.	2.7	66
158	Cost-Effectiveness of Pharmacogenetics-Guided Warfarin Therapy vs. Alternative Anticoagulation in Atrial Fibrillation. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 199-207.	2.3	64
159	Polymorphisms in the TNF- $\alpha$ and TNF-receptor genes in patients with coronary artery disease. <i>European Journal of Clinical Investigation</i> , 2001, 31, 843-851.	1.7	63
160	Adverse drug reactions: back to the future. <i>British Journal of Clinical Pharmacology</i> , 2003, 55, 486-492.	1.1	63
161	Plasma Cysteine Deficiency and Decreased Reduction of Nitrososulfamethoxazole with HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 1929-1938.	0.5	62
162	Exon sequencing and high resolution haplotype analysis of ABC transporter genes implicated in drug resistance. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 439-450.	0.7	62

#	ARTICLE	IF	CITATIONS
163	Acceptance of Biomarker-Based Tests for Application in Clinical Practice: Criteria and Obstacles. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 88, 862-866.	2.3	62
164	Characterization of p-Phenylenediamine-Albumin Binding Sites and T-Cell Responses to Hapten-Modified Protein. <i>Journal of Investigative Dermatology</i> , 2010, 130, 732-742.	0.3	62
165	Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. <i>Thrombosis and Haemostasis</i> , 2012, 107, 232-240.	1.8	62
166	Adverse drug reactions in hospital in-patients: a pilot study. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2006, 31, 335-341.	0.7	61
167	The Phenotype Standardization Project: Improving Pharmacogenetic Studies of Serious Adverse Drug Reactions. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 89, 784-785.	2.3	61
168	Direct oral anticoagulants versus warfarin: is new always better than the old?. <i>Open Heart</i> , 2018, 5, e000712.	0.9	61
169	Recommendations for the Use of Social Media in Pharmacovigilance: Lessons from IMI WEB-RADR. <i>Drug Safety</i> , 2019, 42, 1393-1407.	1.4	60
170	Cost-effectiveness of screening for HLA-A*31:01 prior to initiation of carbamazepine in epilepsy. <i>Epilepsia</i> , 2015, 56, 556-563.	2.6	59
171	Modulation of LAT1 (SLC7A5) transporter activity and stability by membrane cholesterol. <i>Scientific Reports</i> , 2017, 7, 43580.	1.6	59
172	Characterisation and Carriage Ratio of Clostridium difficile Strains Isolated from a Community-Dwelling Elderly Population in the United Kingdom. <i>PLoS ONE</i> , 2011, 6, e22804.	1.1	58
173	In silico analysis of HLA associations with drug-induced liver injury: use of a HLA-genotyped DNA archive from healthy volunteers. <i>Genome Medicine</i> , 2012, 4, 51.	3.6	58
174	Detection of Drug-Induced Acute Kidney Injury in Humans Using Urinary KIM-1, miR-21, -200c, and -423. <i>Toxicological Sciences</i> , 2016, 152, 205-213.	1.4	58
175	Susceptibility to corticosteroid-induced adrenal suppression: a genome-wide association study. <i>Lancet Respiratory Medicine</i> , 2018, 6, 442-450.	5.2	58
176	Drug-Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 245-253.	2.3	58
177	Direct and metabolism-dependent toxicity of sulphasalazine and its principal metabolites towards human erythrocytes and leucocytes. <i>British Journal of Clinical Pharmacology</i> , 1991, 32, 303-310.	1.1	57
178	Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 800-812.	0.7	57
179	Reported paediatric adverse drug reactions in the UK 2000-2009. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 437-446.	1.1	57
180	Parsing interindividual drug variability: an emerging role for systems pharmacology. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2015, 7, 221-241.	6.6	57

#	ARTICLE	IF	CITATIONS
181	Genetics of Immune-Mediated Adverse Drug Reactions: a Comprehensive and Clinical Review. <i>Clinical Reviews in Allergy and Immunology</i> , 2015, 48, 165-175.	2.9	57
182	Characterization of the metabolites of carbamazepine in patient urine by liquid chromatography/mass spectrometry. <i>Drug Metabolism and Disposition</i> , 1997, 25, 275-80.	1.7	57
183	Slow acetylator phenotype and genotype in HIV-positive patients with sulphamethoxazole hypersensitivity. <i>British Journal of Clinical Pharmacology</i> , 2003, 55, 158-165.	1.1	56
184	Assessment of Adipokine Expression and Mitochondrial Toxicity in HIV Patients With Lipoatrophy on Stavudine- and Zidovudine-Containing Regimens. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2005, 40, 565-572.	0.9	56
185	Impact of the CYP4F2 p.V433M Polymorphism on Coumarin Dose Requirement: Systematic Review and Meta-Analysis. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 746-756.	2.3	56
186	N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 1079-1086.	0.8	56
187	<i>HLA*38:02:01</i> predicts carbimazole/methimazole-induced agranulocytosis. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 99, 555-561.	2.3	56
188	The role of <i>Clostridium difficile</i> in the paediatric and neonatal gut – a narrative review. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2016, 35, 1047-1057.	1.3	56
189	Are Chemically Reactive Metabolites Responsible for Adverse Reactions to Drugs?. <i>Current Drug Metabolism</i> , 2002, 3, 351-366.	0.7	56
190	Hepatocellular response to chemical stress in CD-1 mice: Induction of early genes and <sup>3</sup> -glutamylcysteine synthetase. <i>Hepatology</i> , 2000, 32, 321-333.	3.6	55
191	A role for the pregnane X receptor in flucloxacillin-induced liver injury. <i>Hepatology</i> , 2010, 51, 1656-1664.	3.6	55
192	Quantifying the Metabolic Activation of Nevirapine in Patients by Integrated Applications of NMR and Mass Spectrometries. <i>Drug Metabolism and Disposition</i> , 2010, 38, 122-132.	1.7	55
193	The effect of enzyme induction on the cytochrome P450-mediated bioactivation of carbamazepine by mouse liver microsomes. <i>Biochemical Pharmacology</i> , 1992, 44, 2307-2314.	2.0	54
194	Intracellular glutathione in the peripheral blood cells of HIV-infected patients: failure to show a deficiency. <i>Aids</i> , 1996, 10, 501-507.	1.0	54
195	The relative contribution of NSAIDs and <i>Helicobacter pylori</i> to the aetiology of endoscopically diagnosed peptic ulcer disease: observations from a tertiary referral hospital in the UK between 2005 and 2010. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 48-56.	1.9	54
196	Cardiovascular Pharmacogenomics: Expectations and Practical Benefits. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 281-293.	2.3	54
197	Genome-wide Association Study and Meta-analysis on Alcohol-Associated Liver Cirrhosis Identifies Genetic Risk Factors. <i>Hepatology</i> , 2021, 73, 1920-1931.	3.6	54
198	Pharmacovigilance of drug allergy and hypersensitivity using the ENDA “DAHD database and the GA <sup>2</sup> LEN platform. The Galenda project. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2009, 64, 194-203.	2.7	53

#	ARTICLE	IF	CITATIONS
199	Genomics of Adverse Drug Reactions. Trends in Pharmacological Sciences, 2017, 38, 100-109.	4.0	53
200	The molecular genetics of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2017, 120, 127-140.	2.0	53
201	Serious carbamazepine-induced hypersensitivity reactions associated with the HSP70 gene cluster. Pharmacogenetics and Genomics, 2006, 16, 287-296.	0.7	52
202	Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions. Clinical Pharmacology and Therapeutics, 2019, 106, 1028-1036.	2.3	52
203	T-Cells from HLA-B*57:01+ Human Subjects Are Activated with Abacavir through Two Independent Pathways and Induce Cell Death by Multiple Mechanisms. Chemical Research in Toxicology, 2013, 26, 759-766.	1.7	51
204	TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity. Pharmacogenetics and Genomics, 2017, 27, 213-222.	0.7	51
205	Î²-Lactam Antibiotics Form Distinct Haptenic Structures on Albumin and Activate Drug-Specific T-Lymphocyte Responses in Multiallergic Patients with Cystic Fibrosis. Chemical Research in Toxicology, 2013, 26, 963-975.	1.7	50
206	Pharmacogenomics: Current State-of-the-Art. Genes, 2014, 5, 430-443.	1.0	50
207	Reference intervals for urinary renal injury biomarkers KIM-1 and NGAL in healthy children. Biomarkers in Medicine, 2014, 8, 1189-1197.	0.6	50
208	Dexamethasone and haemorrhage risk in paediatric tonsillectomy: a systematic review and meta-analysis. British Journal of Anaesthesia, 2014, 113, 23-42.	1.5	50
209	Pharmacogenetics of antiepileptic drug-induced hypersensitivity. Pharmacogenomics, 2014, 15, 857-868.	0.6	50
210	Genome-wide association study of inhaled corticosteroid response in admixed children with asthma. Clinical and Experimental Allergy, 2019, 49, 789-798.	1.4	50
211	Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography. Leukemia Research, 2010, 34, 702-707.	0.4	49
212	Metabolic acidosis with topiramate and zonisamide. Pharmacogenetics and Genomics, 2011, 21, 297-302.	0.7	49
213	Predictive Genetic Testing for Drug-Induced Liver Injury: Considerations of Clinical Utility. Clinical Pharmacology and Therapeutics, 2012, 92, 376-380.	2.3	49
214	Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout. Rheumatology, 2017, 56, 1729-1739.	0.9	49
215	Adverse drug reactions as a cause of admission to an acute medical assessment unit: a pilot study. Journal of Clinical Pharmacy and Therapeutics, 2000, 25, 355-361.	0.7	49
216	The future prospects of pharmacogenetics in oral anticoagulation therapy. British Journal of Clinical Pharmacology, 2006, 61, 746-751.	1.1	48

#	ARTICLE	IF	CITATIONS
217	Activation of T-Cells from Allergic Patients and Volunteers by p-Phenylenediamine and Bandrowski's Base. <i>Journal of Investigative Dermatology</i> , 2008, 128, 897-905.	0.3	48
218	Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 781-789.	0.7	48
219	Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia. <i>Journal of NeuroVirology</i> , 2016, 22, 852-860.	1.0	48
220	Carbamazepine-hypersensitivity: assessment of clinical and in vitro chemical cross-reactivity with phenytoin and oxcarbazepine. <i>British Journal of Clinical Pharmacology</i> , 1991, 32, 741-9.	1.1	48
221	Functional validity, role, and implications of heavy alcohol consumption genetic loci. <i>Science Advances</i> , 2020, 6, eaay5034.	4.7	47
222	Bioactivation of Clozapine by Murine Cardiac Tissue in Vivo and in Vitro. <i>Chemical Research in Toxicology</i> , 2003, 16, 1359-1364.	1.7	46
223	The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2010, 14, 1-157, iii.	1.3	46
224	Detection of an autoantibody directed against human liver microsomal protein in a patient with carbamazepine hypersensitivity.. <i>British Journal of Clinical Pharmacology</i> , 1992, 33, 183-186.	1.1	45
225	The effect of genetic polymorphisms in CYP2C9 on sulphamethoxazole N-hydroxylation. <i>Pharmacogenetics and Genomics</i> , 1999, 9, 43-54.	5.7	45
226	Carbamazepine-induced acute liver failure as part of the DRESS syndrome. <i>International Journal of Clinical Practice</i> , 2005, 59, 988-991.	0.8	45
227	Common ABCB1 polymorphisms are not associated with multidrug resistance in epilepsy using a gene-wide tagging approach. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 217-220.	0.7	45
228	Identifying the biological pathways underlying human focal epilepsy: from complexity to coherence to centrality. <i>Human Molecular Genetics</i> , 2015, 24, 4306-4316.	1.4	45
229	Reactive metabolites and their role in drug reactions. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2001, 1, 317-325.	1.1	44
230	Genomewide Association Study of Statin-Induced Myopathy in Patients Recruited Using the <sc>UK</sc> Clinical Practice Research Datalink. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1353-1361.	2.3	44
231	Pharmacogenetics of HIV therapy. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 693-703.	0.7	43
232	Genetic variation in <i>CFH</i> predicts phenytoin-induced maculopapular exanthema in European-descent patients. <i>Neurology</i> , 2018, 90, e332-e341.	1.5	43
233	Warfarin dosing algorithms: A systematic review. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1717-1729.	1.1	43
234	THE ROLE OF POLYMORPHISMS OF GLUTATHIONE S-TRANSFERASES GSTM1, M3, P1, T1 AND A1 IN SUSCEPTIBILITY TO ALCOHOLIC LIVER DISEASE. <i>Alcohol and Alcoholism</i> , 2004, 39, 478-483.	0.9	42

#	ARTICLE	IF	CITATIONS
235	Genetics and the Potential for Predictive Tests in Adverse Drug Reactions. <i>Chemical Immunology and Allergy</i> , 2012, 97, 18-31.	1.7	42
236	Reporting of drug induced depression and fatal and non-fatal suicidal behaviour in the UK from 1998 to 2011. <i>BMC Pharmacology &amp; Toxicology</i> , 2014, 15, 54.	1.0	42
237	Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw545.	1.3	42
238	Global Pharmacogenomics Within Precision Medicine: Challenges and Opportunities. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 57-61.	2.3	42
239	Intracellular Disposition and Metabolic Effects of Zidovudine, Stavudine and Four Protease Inhibitors in Cultured Adipocytes. <i>Antiviral Therapy</i> , 2003, 8, 417-426.	0.6	42
240	Glutathione S-transferase mu genotype (GSTM1*0) in Alzheimer's patients with tacrine transaminitis.. <i>British Journal of Clinical Pharmacology</i> , 1995, 39, 411-415.	1.1	41
241	Safety assessment of peroxide antimalarials: clinical and chemical perspectives. <i>British Journal of Clinical Pharmacology</i> , 1998, 46, 521-529.	1.1	41
242	Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: the role of nuclear hormone response elements. <i>British Journal of Clinical Pharmacology</i> , 2006, 62, 237-242.	1.1	41
243	Promiscuous T-cell responses to drugs and drug-haptens. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 474-476.e8.	1.5	41
244	A multi-factorial analysis of response to warfarin in a UK prospective cohort. <i>Genome Medicine</i> , 2016, 8, 2.	3.6	41
245	The Effect of Inhibitory Signals on the Priming of Drug Hapten-Specific T Cells That Express Distinct V $\beta$ <sup>2</sup> Receptors. <i>Journal of Immunology</i> , 2017, 199, 1223-1237.	0.4	41
246	A common missense variant of LILRB5 is associated with statin intolerance and myalgia. <i>European Heart Journal</i> , 2017, 38, 3569-3575.	1.0	41
247	Adaptation of host transmission cycle during <i>Clostridium difficile</i> speciation. <i>Nature Genetics</i> , 2019, 51, 1315-1320.	9.4	41
248	SJS/TEN 2019: From science to translation. <i>Journal of Dermatological Science</i> , 2020, 98, 2-12.	1.0	41
249	The relationship between the disposition and immunogenicity of sulfamethoxazole in the rat. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1997, 282, 795-801.	1.3	41
250	Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1889-1893.	1.3	40
251	Detection of Primary T Cell Responses to Drugs and Chemicals in HLA-Typed Volunteers: Implications for the Prediction of Drug Immunogenicity. <i>Toxicological Sciences</i> , 2016, 154, 416-429.	1.4	40
252	Genetic Factors Influencing Warfarin Dose in Black African Patients: A Systematic Review and Meta-Analysis. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 1420-1433.	2.3	40

#	ARTICLE	IF	CITATIONS
253	HIV and drug allergy. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2001, 1, 311-316.	1.1	40
254	Altered Adipokine Response in Murine 3T3-F442A Adipocytes Treated with Protease Inhibitors and Nucleoside Reverse Transcriptase Inhibitors. <i>Antiviral Therapy</i> , 2005, 10, 207-213.	0.6	40
255	Pre-registration nurse education in pharmacology: is it adequate for the roles that nurses are expected to fulfil?. <i>Nurse Education Today</i> , 2002, 22, 447-456.	1.4	39
256	Statins inhibit aminoglycoside accumulation and cytotoxicity to renal proximal tubule cells. <i>Biochemical Pharmacology</i> , 2010, 79, 647-654.	2.0	39
257	Pharmacogenetic tests: the need for a level playing field. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 3-4.	21.5	39
258	Paediatric use of mycophenolate mofetil. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 45-59.	1.1	39
259	Calprotectin and Lactoferrin Faecal Levels in Patients with Clostridium difficile Infection (CDI): A Prospective Cohort Study. <i>PLoS ONE</i> , 2014, 9, e106118.	1.1	39
260	Immunopharmacology of hypersensitivity reactions to drugs. <i>Current Allergy and Asthma Reports</i> , 2003, 3, 22-29.	2.4	38
261	Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. <i>Pharmacogenetics and Genomics</i> , 2012, 22, 10-19.	0.7	38
262	Tacrine-induced liver damage: an analysis of 19 candidate genes. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 1091-1100.	0.7	37
263	Current Assessment of Risk-Benefit by Regulators: Is It Time to Introduce Decision Analyses?. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 82, 123-127.	2.3	37
264	Investigation of inter-individual variability of the one-carbon folate pathway: a bioinformatic and genetic review. <i>Pharmacogenomics Journal</i> , 2009, 9, 291-305.	0.9	37
265	Identifying new antiepileptic drugs through genomics-based drug repurposing. <i>Human Molecular Genetics</i> , 2017, 26, ddd410.	1.4	37
266	Pre-registration nurse education in pharmacology: is it adequate for the roles that nurses are expected to fulfil?. , 2002, 22, 447-447.		37
267	Exploring the genomic basis of pharmacoresistance in epilepsy: an integrative analysis of large-scale gene expression profiling studies on brain tissue from epilepsy surgery. <i>Human Molecular Genetics</i> , 2011, 20, 4381-4394.	1.4	36
268	CYP2B6 c.983T>C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3329-3334.	1.3	36
269	HLA Restriction of Carbamazepine-Specific T-Cell Clones from an HLA-A*31:01-Positive Hypersensitive Patient. <i>Chemical Research in Toxicology</i> , 2014, 27, 175-177.	1.7	36
270	The recent emergence of a highly related virulent Clostridium difficile clade with unique characteristics. <i>Clinical Microbiology and Infection</i> , 2020, 26, 492-498.	2.8	36



#	ARTICLE	IF	CITATIONS
271	GENERAL PRACTICE NURSES' KNOWLEDGE OF ALCOHOL USE AND MISUSE: A QUESTIONNAIRE SURVEY. <i>Alcohol and Alcoholism</i> , 2000, 35, 259-262.	0.9	35
272	The pharmacogenomics of HIV therapy. <i>Pharmacogenomics Journal</i> , 2001, 1, 243-253.	0.9	35
273	Important questions in Allergy: 1 " drug allergy/hypersensitivity. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 616-619.	2.7	35
274	Measurement of CD4+ and CD8+ T-Lymphocyte Cytokine Secretion and Gene Expression Changes in p-Phenylenediamine Allergic Patients and Tolerant Individuals. <i>Journal of Investigative Dermatology</i> , 2010, 130, 161-174.	0.3	35
275	Drug-induced hypersensitivity reactions and pharmacogenomics: past, present and future. <i>Pharmacogenomics</i> , 2010, 11, 497-499.	0.6	35
276	CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia. <i>Blood</i> , 2013, 122, 4253-4258.	0.6	35
277	The effect of fluconazole and ketoconazole on the metabolism of sulphamethoxazole. <i>British Journal of Clinical Pharmacology</i> , 1996, 42, 347-353.	1.1	34
278	Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study. <i>BMC Medicine</i> , 2019, 17, 76.	2.3	34
279	Genetic Association of Co-trimoxazole-Induced Severe Cutaneous Adverse Reactions Is Phenotype-Specific: HLA Class I Genotypes and Haplotypes. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 1078-1089.	2.3	34
280	Disposition of amodiaquine and related antimalarial agents in human neutrophils: implications for drug design. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1997, 280, 884-93.	1.3	34
281	Investigation into the multidimensional genetic basis of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis. <i>Pharmacogenomics</i> , 2007, 8, 1661-1691.	0.6	33
282	Pharmacogenomics in neurology: Current state and future steps. <i>Annals of Neurology</i> , 2011, 70, 684-697.	2.8	33
283	Early Deaths During Tuberculosis Treatment Are Associated With Depressed Innate Responses, Bacterial Infection, and Tuberculosis Progression. <i>Journal of Infectious Diseases</i> , 2011, 204, 358-362.	1.9	33
284	A genome-wide association study and biological pathway analysis of epilepsy prognosis in a prospective cohort of newly treated epilepsy. <i>Human Molecular Genetics</i> , 2014, 23, 247-258.	1.4	33
285	Genotype-guided versus standard vitamin K antagonist dosing algorithms in patients initiating anticoagulation. <i>Thrombosis and Haemostasis</i> , 2015, 114, 768-777.	1.8	33
286	A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. <i>Journal of Hepatology</i> , 2022, 76, 275-282.	1.8	33
287	Adverse drug reactions, multimorbidity and polypharmacy: a prospective analysis of 1 month of medical admissions. <i>BMJ Open</i> , 2022, 12, e055551.	0.8	33
288	<i>Clinical Pharmacology. Drug Safety</i> , 2004, 27, 535-554.	1.4	32

#	ARTICLE	IF	CITATIONS
289	Pharmacogenetic Markers of Drug Efficacy and Toxicity. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 98, 61-70.	2.3	32
290	Pharmacogenetics of Adverse Drug Reactions. <i>Advances in Pharmacology</i> , 2018, 83, 155-190.	1.2	32
291	Personalized medicine: decades away?. <i>Pharmacogenomics</i> , 2006, 7, 237-241.	0.6	31
292	Drug Induced Hypersensitivity and the HLA Complex. <i>Pharmaceuticals</i> , 2011, 4, 69-90.	1.7	31
293	Genome-wide association study of serious blistering skin rash caused by drugs. <i>Pharmacogenomics Journal</i> , 2012, 12, 96-104.	0.9	31
294	The <em>HLA-A*31:01</em> allele: influence on carbamazepine treatment. <i>Pharmacogenomics and Personalized Medicine</i> , 2017, Volume10, 29-38.	0.4	31
295	Genetic Risk Factors in Drug-Induced Liver Injury Due to Isoniazid-Containing Antituberculosis Drug Regimens. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1125-1135.	2.3	31
296	Molecular and genetic association of interleukin-6 in tacrine-induced hepatotoxicity. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 961-972.	0.7	30
297	Pharmacogenomics: the importance of accurate phenotypes. <i>Pharmacogenomics</i> , 2010, 11, 469-470.	0.6	30
298	CYP2C19*17 Gain-of-Function Polymorphism Is Associated With Peptic Ulcer Disease. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 93, 195-203.	2.3	30
299	Expanding Role of Pharmacogenomics in the Management of Cardiovascular Disorders. <i>American Journal of Cardiovascular Drugs</i> , 2013, 13, 151-162.	1.0	30
300	GATM gene variants and statin myopathy risk. <i>Nature</i> , 2014, 513, E1-E1.	13.7	30
301	Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Standard Reporting and Evaluation Guidelines. <i>JAMA Dermatology</i> , 2017, 153, 587.	2.0	30
302	Rationale and design of the multiethnic Pharmacogenomics in Childhood Asthma consortium. <i>Pharmacogenomics</i> , 2017, 18, 931-943.	0.6	30
303	New uses for old drugs. <i>BMJ: British Medical Journal</i> , 2018, 361, k2701.	2.4	30
304	Cellular Uptake of the Atypical Antipsychotic Clozapine Is a Carrier-Mediated Process. <i>Molecular Pharmaceutics</i> , 2018, 15, 3557-3572.	2.3	30
305	A Framework for Multi-Omic Prediction of Treatment Response to Biologic Therapy for Psoriasis. <i>Journal of Investigative Dermatology</i> , 2019, 139, 100-107.	0.3	30
306	Pharmacogenomics for Primary Care: An Overview. <i>Genes</i> , 2020, 11, 1337.	1.0	30

#	ARTICLE	IF	CITATIONS
307	Pharmacogenomics of NSAID-Induced Upper Gastrointestinal Toxicity. <i>Frontiers in Pharmacology</i> , 2021, 12, 684162.	1.6	30
308	The quality of information on monitoring for haematological adverse drug reactions. <i>British Journal of Clinical Pharmacology</i> , 2005, 60, 448-451.	1.1	29
309	The use of opioids and laxatives, and incidence of constipation, in patients requiring neck-of-femur (NOF) surgery: a pilot study. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2008, 33, 561-566.	0.7	29
310	Effect of atazanavir and ritonavir on the differentiation and adipokine secretion of human subcutaneous and omental preadipocytes. <i>Aids</i> , 2008, 22, 1293-1298.	1.0	29
311	<i>TNF</i> , <i>LTA</i> , <i>HSPA1L</i> and <i>HLA-DR</i> gene polymorphisms in HIV-positive patients with hypersensitivity to cotrimoxazole. <i>Pharmacogenomics</i> , 2009, 10, 531-540.	0.6	29
312	Genome-wide association study of warfarin maintenance dose in a Brazilian sample. <i>Pharmacogenomics</i> , 2015, 16, 1253-1263.	0.6	29
313	Advances in the Pharmacogenomics of Adverse Drug Reactions. <i>Drug Safety</i> , 2016, 39, 15-27.	1.4	29
314	HLA-B*13 :01 Is a Predictive Marker of Dapsone-Induced Severe Cutaneous Adverse Reactions in Thai Patients. <i>Frontiers in Immunology</i> , 2021, 12, 661135.	2.2	29
315	Causality Patterns for Detecting Adverse Drug Reactions From Social Media: Text Mining Approach. <i>JMIR Public Health and Surveillance</i> , 2018, 4, e51.	1.2	29
316	Folate Augmentation of Treatment " Evaluation for Depression (FolATED): protocol of a randomised controlled trial. <i>BMC Psychiatry</i> , 2007, 7, 65.	1.1	28
317	Pharmacogenetics of Idiosyncratic Adverse Drug Reactions. <i>Handbook of Experimental Pharmacology</i> , 2010, , 477-491.	0.9	28
318	Pharmacogenetic testing prior to carbamazepine treatment of epilepsy: patients' and physicians' preferences for testing and service delivery. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1149-1159.	1.1	28
319	Quality of life in patients with venous thromboembolism and atrial fibrillation treated with coumarin anticoagulants. <i>Thrombosis Research</i> , 2015, 136, 69-75.	0.8	28
320	Identification of Organ-Enriched Protein Biomarkers of Acute Liver Injury by Targeted Quantitative Proteomics of Blood in Acetaminophen- and Carbon-Tetrachloride-Treated Mouse Models and Acetaminophen Overdose Patients. <i>Journal of Proteome Research</i> , 2016, 15, 3724-3740.	1.8	28
321	The implementation of pharmacogenomics into UK general practice: a qualitative study exploring barriers, challenges and opportunities. <i>Journal of Community Genetics</i> , 2020, 11, 269-277.	0.5	28
322	A Genome-wide Association Study of Circulating Levels of Atorvastatin and Its Major Metabolites. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 287-297.	2.3	28
323	Drug therapy for alcohol dependence in primary care in the UK: A Clinical Practice Research Datalink study. <i>PLoS ONE</i> , 2017, 12, e0173272.	1.1	28
324	Folate Augmentation of Treatment " Evaluation for Depression (FolATED): randomised trial and economic evaluation. <i>Health Technology Assessment</i> , 2014, 18, 1-160.	1.3	28

#	ARTICLE	IF	CITATIONS
325	Monitoring drug treatment. <i>BMJ: British Medical Journal</i> , 2003, 327, 1179-1181.	2.4	27
326	Adverse drug reactions causing admission to a paediatric hospital: a pilot study. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2011, 36, 194-199.	0.7	27
327	Predictors and outcomes of increases in creatine phosphokinase concentrations or rhabdomyolysis risk during statin treatment. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 649-659.	1.1	27
328	Thiopurine monitoring in children with inflammatory bowel disease: a systematic review. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 467-476.	1.1	27
329	Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden. <i>Pharmacogenomics Journal</i> , 2016, 16, 478-484.	0.9	27
330	A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives. <i>Pharmacogenomics</i> , 2010, 11, 989-1002.	0.6	26
331	Brief Interventions in Dependent Drinkers: A Comparative Prospective Analysis in Two Hospitals. <i>Alcohol and Alcoholism</i> , 2011, 46, 434-440.	0.9	26
332	Variability of antibiotic prescribing in patients with chronic obstructive pulmonary disease exacerbations: a cohort study. <i>BMC Pulmonary Medicine</i> , 2013, 13, 32.	0.8	26
333	ABCB1 single nucleotide polymorphisms (1236C>T, 2677G>T, and 3435C>T) do not affect transport activity of human P-glycoprotein. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 314-323.	0.7	26
334	Genotype-Guided Dosing of Vitamin K Antagonists. <i>New England Journal of Medicine</i> , 2014, 370, 1761-1766.	13.9	26
335	HLA-allele associations with nevirapine-induced hypersensitivity reactions and hepatotoxicity. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 186-198.	0.7	26
336	Development of the Liverpool Adverse Drug Reaction Avoidability Assessment Tool. <i>PLoS ONE</i> , 2017, 12, e0169393.	1.1	26
337	Warfarin: The End or the End of One Size Fits All Therapy?. <i>Journal of Personalized Medicine</i> , 2018, 8, 22.	1.1	26
338	Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study. <i>Pharmacogenetics and Genomics</i> , 2020, 30, 131-144.	0.7	26
339	Beta-lactam-induced immediate hypersensitivity reactions: A genome-wide association study of a deeply phenotyped cohort. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 1830-1837.e15.	1.5	26
340	Identifying cisplatin-induced kidney damage in paediatric oncology patients. <i>Pediatric Nephrology</i> , 2018, 33, 1467-1474.	0.9	25
341	Biomarkers of adverse drug reactions. <i>Experimental Biology and Medicine</i> , 2018, 243, 291-299.	1.1	25
342	Renal function monitoring in heart failure – what is the optimal frequency? A narrative review. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 5-17.	1.1	25

#	ARTICLE	IF	CITATIONS
343	Costâ€Effectiveness of Panel Tests for Multiple Pharmacogenes Associated With Adverse Drug Reactions: An Evaluation Framework. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1429-1438.	2.3	25
344	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. <i>PLoS ONE</i> , 2020, 15, e0227458.	1.1	25
345	A Multi-System Approach Assessing the Interaction of Anticonvulsants with P-gp. <i>PLoS ONE</i> , 2013, 8, e64854.	1.1	25
346	Obesity, Diabetes, Coffee, Tea, and Cannabis Use Alter Risk for Alcohol-Related Cirrhosis in 2 Large Cohorts of High-Risk Drinkers. <i>American Journal of Gastroenterology</i> , 2021, 116, 106-115.	0.2	25
347	Paediatric pharmacogenomics: an overview. <i>Archives of Disease in Childhood</i> , 2013, 98, 232-237.	1.0	24
348	Population Pharmacokinetic and Pharmacogenetic Analysis of Nevirapine in Hypersensitive and Tolerant HIV-Infected Patients from Malawi. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 706-712.	1.4	24
349	Adrenal responses to a lowâ€dose short synacthen test in children with asthma. <i>Clinical Endocrinology</i> , 2015, 82, 648-656.	1.2	24
350	An assessment of the impact of pharmacogenomics on health disparities: a systematic literature review. <i>Pharmacogenomics</i> , 2017, 18, 1541-1550.	0.6	24
351	Defining drug response for stratified medicine. <i>Drug Discovery Today</i> , 2017, 22, 173-179.	3.2	24
352	What are the social predictors of accident and emergency attendance in disadvantaged neighbourhoods? Results from a cross-sectional household health survey in the north west of England. <i>BMJ Open</i> , 2019, 9, e022820.	0.8	24
353	Genetic associations with clozapine-induced myocarditis in patients with schizophrenia. <i>Translational Psychiatry</i> , 2020, 10, 37.	2.4	24
354	In Vivo and In Vitro Efficacy of Amodiaquine against <i>Plasmodium falciparum</i> in an Area of Continued Use of 4â€Aminoquinolines in East Africa. <i>Journal of Infectious Diseases</i> , 2009, 199, 1575-1582.	1.9	23
355	What can we learn from parents about enhancing participation in pharmacovigilance?. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 1109-1117.	1.1	23
356	The International Serious Adverse Events Consortium (iSAEC) phenotype standardization project for drug-induced torsades de pointes. <i>European Heart Journal</i> , 2013, 34, 1958-1963.	1.0	23
357	Effect of <i>CYP4F2</i> , <i>VKORC1</i> , and <i>CYP2C9</i> in Influencing Coumarin Dose: A Singleâ€Patient Data Metaâ€Analysis in More Than 15,000 Individuals. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1477-1491.	2.3	23
358	The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 85-99.	1.4	23
359	Reactive metabolites and their role in drug reactions. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2001, 1, 317-325.	1.1	23
360	Lymphocyte microsomal epoxide hydrolase in patients on carbamazepine therapy.. <i>British Journal of Clinical Pharmacology</i> , 1994, 37, 577-581.	1.1	22

#	ARTICLE	IF	CITATIONS
361	Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2008, 49, 639-642.	0.6	22
362	CSF/plasma HIV-1 RNA discordance even at low levels is associated with up-regulation of host inflammatory mediators in CSF. <i>Cytokine</i> , 2016, 83, 139-146.	1.4	22
363	Mass Spectrometric Characterization of Circulating Covalent Protein Adducts Derived from Epoxide Metabolites of Carbamazepine in Patients. <i>Chemical Research in Toxicology</i> , 2017, 30, 1419-1435.	1.7	22
364	17q21 variant increases the risk of exacerbations in asthmatic children despite inhaled corticosteroids use. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 2083-2088.	2.7	22
365	Emerging technologies and their impact on regulatory science. <i>Experimental Biology and Medicine</i> , 2022, 247, 1-75.	1.1	22
366	Adverse drug reactions and pharmacogenomics: recent advances. <i>Personalized Medicine</i> , 2008, 5, 11-23.	0.8	21
367	The d3/fI-GH receptor gene polymorphism does not influence quality of life and body composition in GH-deficient adults receiving GH replacement therapy. <i>European Journal of Endocrinology</i> , 2009, 161, 541-546.	1.9	21
368	Comparative Effectiveness of Dabigatran, Rivaroxaban, Apixaban, and Warfarin in the Management of Patients With Nonvalvular Atrial Fibrillation. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 269-276.	2.3	21
369	Effect of Genetic Variability in the CYP4F2, CYP4F11, and CYP4F12 Genes on Liver mRNA Levels and Warfarin Response. <i>Frontiers in Pharmacology</i> , 2017, 8, 323.	1.6	21
370	The prescribable drugs with efficacy in experimental epilepsies (<sc>PDE</sc>3) database for drug repurposing research in epilepsy. <i>Epilepsia</i> , 2018, 59, 492-501.	2.6	21
371	Toxicogenetics in drug development. <i>Toxicology Letters</i> , 2001, 120, 281-291.	0.4	20
372	Whole-blood cultures from renal-transplant patients stimulated ex vivo show that the effects of cyclosporine on lymphocyte proliferation are related to P-glycoprotein expression. <i>Transplantation</i> , 2004, 77, 557-561.	0.5	20
373	Drug-drug interactions and adverse drug reactions: separating the wheat from the chaff. <i>Wiener Klinische Wochenschrift</i> , 2010, 122, 62-64.	1.0	20
374	The clinical significance of ABCC3 as an imatinib transporter in chronic myeloid leukaemia. <i>Leukemia</i> , 2014, 28, 1360-1363.	3.3	20
375	Investigating the prevalence, predictors, and prognosis of suboptimal statin use early after a non-ST elevation acute coronary syndrome. <i>Journal of Clinical Lipidology</i> , 2017, 11, 204-214.	0.6	20
376	Genetic regulation of gene expression in the epileptic human hippocampus. <i>Human Molecular Genetics</i> , 2017, 26, 1759-1769.	1.4	20
377	A call for the appropriate application of clinical pharmacological principles in the search for safe and efficacious COVID-19 (SARS-CoV-2) treatments. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 707-711.	1.1	20
378	A population study of clinically actionable genetic variation affecting drug response from the Middle East. <i>Npj Genomic Medicine</i> , 2022, 7, 10.	1.7	20

#	ARTICLE	IF	CITATIONS
379	Pharmacogenomics decision support in the U-PGx project: Results and advice from clinical implementation across seven European countries. <i>PLoS ONE</i> , 2022, 17, e0268534.	1.1	20
380	Idiosyncratic reactions to antidepressants: A review of the possible mechanisms and predisposing factors. , 1992, 53, 105-125.		19
381	Bioactivation and bioinactivation of drugs and drug metabolites: Relevance to adverse drug reactions. <i>Toxicology in Vitro</i> , 1994, 8, 613-621.	1.1	19
382	Beyond registrationâ€”measuring the public-health potential of new treatments for malaria in Africa. <i>Lancet Infectious Diseases</i> , The, 2006, 6, 46-52.	4.6	19
383	<i>ST13</i> polymorphisms and their effect on exacerbations in steroidâ€”treated asthmatic children and young adults. <i>Clinical and Experimental Allergy</i> , 2015, 45, 1051-1059.	1.4	19
384	Towards better models and mechanistic biomarkers for drug-induced gastrointestinal injury. , 2017, 172, 181-194.		19
385	A prospective cohort study examining the effectiveness of baclofen in the maintenance of abstinence in alcohol use disorder patients attending a joint liver and alcohol treatment clinic. <i>Alcohol</i> , 2017, 62, 11-15.	0.8	19
386	Characterization of Circulating Clostridium difficile Strains, Host Response and Intestinal Microbiome in Hospitalized Children With Diarrhea. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, 221-228.	1.1	19
387	Roadmap to 2030 for Drug Evaluation in Older Adults. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 210-223.	2.3	19
388	Characterization of the T-Cell Response in a Patient with Phenindione Hypersensitivity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 313, 1058-1065.	1.3	18
389	Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with <i>CYP2B6</i> c.516Gâ†’T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4511-4518.	1.4	18
390	Precision Dosing in Children. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 69-78.	0.4	18
391	New Approaches to Investigate Drug-Induced Hypersensitivity. <i>Chemical Research in Toxicology</i> , 2017, 30, 239-259.	1.7	18
392	Pharmacogenomics of statin-related myopathy: Meta-analysis of rare variants from whole-exome sequencing. <i>PLoS ONE</i> , 2019, 14, e0218115.	1.1	18
393	Warfarin Pharmacogenetics. <i>Pharmacoeconomics</i> , 2007, 25, 899-902.	1.7	17
394	Effects of genetic variation at the <i>CYP2C19</i>/<i>CYP2C9</i> locus on pharmacokinetics of chlorcycloguanil in adult Gambians. <i>Pharmacogenomics</i> , 2009, 10, 1423-1431.	0.6	17
395	Costâ€”effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs. <i>Pharmacogenomics</i> , 2012, 13, 1405-1417.	0.6	17
396	Enhancing Communication about Paediatric Medicines: Lessons from a Qualitative Study of Parents' Experiences of Their Child's Suspected Adverse Drug Reaction. <i>PLoS ONE</i> , 2012, 7, e46022.	1.1	17

#	ARTICLE	IF	CITATIONS
397	Immunoglobulin G1 and immunoglobulin G4 antibodies in multiple sclerosis patients treated with IFN $\beta$ interact with the endogenous cytokine and activate complement. <i>Clinical Immunology</i> , 2013, 148, 177-185.	1.4	17
398	Through a Glass Darkly: Economics and Personalised Medicine. <i>Pharmacoeconomics</i> , 2014, 32, 1055-1061.	1.7	17
399	Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects. <i>Pharmacogenomics Journal</i> , 2014, 14, 542-548.	0.9	17
400	Development of interferon beta-neutralising antibodies in multiple sclerosis—a systematic review and meta-analysis. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1287-1298.	0.8	17
401	Has the introduction of direct oral anticoagulants (DOACs) in England increased emergency admissions for bleeding conditions? A longitudinal ecological study. <i>BMJ Open</i> , 2020, 10, e033357.	0.8	17
402	Dimethyl fumarate induced lymphopenia in multiple sclerosis: A review of the literature. , 2021, 219, 107710.		17
403	Genome-wide association study of asthma exacerbations despite inhaled corticosteroid use. <i>European Respiratory Journal</i> , 2021, 57, 2003388.	3.1	17
404	ADRIC: Adverse Drug Reactions In Children—a programme of research using mixed methods. <i>Programme Grants for Applied Research</i> , 2014, 2, 1-184.	0.4	17
405	Ethnic Diversity and Warfarin Pharmacogenomics. <i>Frontiers in Pharmacology</i> , 2022, 13, 866058.	1.6	17
406	No association between tacrine transaminitis and the glutathione transferase $\alpha$ genotype in patients with Alzheimer's disease. <i>Pharmacogenetics and Genomics</i> , 1998, 8, 853-355.	5.7	16
407	LC determination of carbamazepine in murine brain. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2001, 26, 573-577.	1.4	16
408	Collecting and sharing information about harms. <i>BMJ: British Medical Journal</i> , 2004, 329, 6-7.	2.4	16
409	Drugs and the retina. <i>Expert Opinion on Drug Safety</i> , 2004, 3, 249-259.	1.0	16
410	HOW DO NHS GENERAL HOSPITALS IN ENGLAND DEAL WITH PATIENTS WITH ALCOHOL-RELATED PROBLEMS? A QUESTIONNAIRE SURVEY. <i>Alcohol and Alcoholism</i> , 2005, 40, 409-412.	0.9	16
411	The association between polymorphisms in <i>RLIP76</i> and drug response in epilepsy. <i>Pharmacogenomics</i> , 2007, 8, 1715-1722.	0.6	16
412	The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein. <i>Biochemical and Biophysical Research Communications</i> , 2011, 408, 344-349.	1.0	16
413	<i>In Vitro</i> Priming of Naïve T-cells with <i>p</i> -Phenylenediamine and Bandrowski's Base. <i>Chemical Research in Toxicology</i> , 2015, 28, 2069-2077.	1.7	16
414	Development of ELISAs for diagnosis of acute typhoid fever in Nigerian children. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005679.	1.3	16



#	ARTICLE	IF	CITATIONS
415	Application of in Vitro T Cell Assay Using Human Leukocyte Antigen-Typed Healthy Donors for the Assessment of Drug Immunogenicity. <i>Chemical Research in Toxicology</i> , 2018, 31, 165-167.	1.7	16
416	Development, validation and application of a novel HPLC-MS/MS method for the quantification of atorvastatin, bisoprolol and clopidogrel in a large cardiovascular patient cohort. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 159, 272-281.	1.4	16
417	Urinary Biomarkers of Aminoglycoside-Induced Nephrotoxicity in Cystic Fibrosis: Kidney Injury Molecule-1 and Neutrophil Gelatinase-Associated Lipocalin. <i>Scientific Reports</i> , 2018, 8, 5094.	1.6	16
418	Software for Dosage Individualization of Voriconazole: a Prospective Clinical Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	16
419	Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvement. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1135-1141.	0.8	16
420	Genetic variants associated with T cell-mediated cutaneous adverse drug reactions: A PRISMA-compliant systematic review An EAACI position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1069-1098.	2.7	16
421	Cardiovascular drugs and COVID-19 clinical outcomes: A living systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4534-4545.	1.1	16
422	Length of Variable Numbers of Tandem Repeats in the Carboxyl Ester Lipase (CEL) Gene May Confer Susceptibility to Alcoholic Liver Cirrhosis but Not Alcoholic Chronic Pancreatitis. <i>PLoS ONE</i> , 2016, 11, e0165567.	1.1	16
423	Immunological principles of T-cell-mediated adverse drug reactions in skin. <i>Expert Opinion on Drug Safety</i> , 2007, 6, 109-124.	1.0	15
424	Herbal medicines and acute medical emergency admissions to hospital. <i>British Journal of Clinical Pharmacology</i> , 2007, 63, 247-248.	1.1	15
425	An evaluation of gene-gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 767-772.	1.9	15
426	Validation of a multigenic model to predict seizure control in newly treated epilepsy. <i>Epilepsy Research</i> , 2014, 108, 1797-1805.	0.8	15
427	Patients Benefit From Genetics-Guided Coumarin Anticoagulant Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 15-17.	2.3	15
428	Serum Mannose-Binding Lectin Concentration, but Not Genotype, Is Associated With <i>Clostridium difficile</i> Infection Recurrence: A Prospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2014, 59, 1429-1436.	2.9	15
429	Phenotype Standardization of Angioedema in the Head and Neck Region Caused by Agents Acting on the Angiotensin System. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 477-481.	2.3	15
430	Systematic review: Baclofen dosing protocols for alcohol use disorders used in observational studies. <i>European Neuropsychopharmacology</i> , 2017, 27, 1077-1089.	0.3	15
431	Research Directions in Genetic Predispositions to Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 390-394.	2.3	15
432	Serum and blister fluid elevation and decreased epidermal content of high-mobility group box 1 protein in drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. <i>British Journal of Dermatology</i> , 2019, 181, 166-174.	1.4	15

#	ARTICLE	IF	CITATIONS
433	Pharmacogenomics in the UK National Health Service: opportunities and challenges. <i>Pharmacogenomics</i> , 2020, 21, 1237-1246.	0.6	15
434	Use of adrenal arterial embolization in severe ACTH-dependent Cushing's syndrome.. <i>Postgraduate Medical Journal</i> , 1989, 65, 575-579.	0.9	14
435	Kinetic parameters of lymphocyte microsomal epoxide hydrolase in carbamazepine hypersensitive patients. <i>Biochemical Pharmacology</i> , 1995, 50, 1361-1366.	2.0	14
436	Lack of association between schizophrenia and the CYP2D6 gene polymorphisms. <i>American Journal of Medical Genetics Part A</i> , 1996, 67, 236-237.	2.4	14
437	Communication regarding adverse drug reactions between secondary and primary care: a postal questionnaire survey of general practitioners. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 1999, 24, 133-139.	0.7	14
438	Pharmacogenetics in reproductive and perinatal medicine. <i>Pharmacogenomics</i> , 2010, 11, 65-79.	0.6	14
439	Monocyte unresponsiveness and impaired IL1 $\beta$ , TNF $\alpha$ and IL7 production are associated with a poor outcome in Malawian adults with pulmonary tuberculosis. <i>BMC Infectious Diseases</i> , 2015, 15, 513.	1.3	14
440	Misoprostol-induced fever and genetic polymorphisms in drug transporters <i>SLCO1B1</i> and <i>ABCC4</i> in women of Latin American and European ancestry. <i>Pharmacogenomics</i> , 2015, 16, 919-928.	0.6	14
441	HLA DRB1*15:01-DQB1*06:02-Restricted Human CD4+ T Cells Are Selectively Activated With Amoxicillin-Peptide Adducts. <i>Toxicological Sciences</i> , 2020, 178, 115-126.	1.4	14
442	Pharmacogenomics of anticancer drugs: Personalising the choice and dose to manage drug response. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 237-255.	1.1	14
443	Characterization of T-Cell Responses to SMX and SMX-NO in Co-Trimoxazole Hypersensitivity Patients Expressing HLA-B*13:01. <i>Frontiers in Immunology</i> , 2021, 12, 658593.	2.2	14
444	Specialist nurse reporting of adverse drug reactions. <i>Professional Nurse (London, England)</i> , 2000, 15, 300-4.	0.1	14
445	Intracellular disposition and metabolic effects of zidovudine, stavudine and four protease inhibitors in cultured adipocytes. <i>Antiviral Therapy</i> , 2003, 8, 417-26.	0.6	14
446	Multi-ancestry genome-wide association study of asthma exacerbations. <i>Pediatric Allergy and Immunology</i> , 2022, 33, .	1.1	14
447	Pharmacogenetics in clinical practice: considerations for testing. <i>Expert Review of Molecular Diagnostics</i> , 2006, 6, 193-205.	1.5	13
448	Adherence and variability in warfarin dose requirements: assessment in a prospective cohort. <i>Pharmacogenomics</i> , 2013, 14, 151-163.	0.6	13
449	Dual Glutathione-S-Transferase $\gamma$ 1 and $\gamma$ 1 Gene Deletions Determine Imatinib Failure in Chronic Myeloid Leukemia. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 694-703.	2.3	13
450	High mobility group box 1 in the inflammatory pathogenesis of epilepsy: profiling circulating levels after experimental and clinical seizures. <i>Lancet, The</i> , 2014, 383, S105.	6.3	13

#	ARTICLE	IF	CITATIONS
451	Achieving the World Health Organization's vision for clinical pharmacology. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 223-227.	1.1	13
452	How important is aspirin adherence when evaluating effectiveness of low-dose aspirin?. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017, 219, 1-9.	0.5	13
453	Evaluation of laboratory tests for cirrhosis and for alcohol use, in the context of alcoholic cirrhosis. <i>Alcohol</i> , 2018, 66, 1-7.	0.8	13
454	Multimorbidity, polypharmacy, and drug-drug-gene interactions following a non-ST elevation acute coronary syndrome: analysis of a multicentre observational study. <i>BMC Medicine</i> , 2020, 18, 367.	2.3	13
455	Improving anticoagulation in sub-Saharan Africa: What are the challenges and how can we overcome them?. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3056-3068.	1.1	13
456	Nilotinib-induced metabolic dysfunction: insights from a translational study using in vitro adipocyte models and patient cohorts. <i>Leukemia</i> , 2019, 33, 1810-1814.	3.3	13
457	Checkpoint Inhibition Reduces the Threshold for Drug-Specific T-Cell Priming and Increases the Incidence of Sulfasalazine Hypersensitivity. <i>Toxicological Sciences</i> , 2022, 186, 58-69.	1.4	13
458	The role of polymorphism in manganese superoxide dismutase in susceptibility to alcoholic liver disease. <i>Gastroenterology</i> , 2003, 124, 2000-2002.	0.6	12
459	Spontaneous Hemothorax Following Anticoagulation with Low-Molecular-Weight Heparin. <i>Annals of Pharmacotherapy</i> , 2009, 43, 1528-1531.	0.9	12
460	Randomized Controlled Trial: Lisinopril Reduces Proteinuria, Ammonia, and Renal Polypeptide Tubular Catabolism in Patients With Chronic Allograft Nephropathy. <i>Transplantation</i> , 2010, 89, 104-114.	0.5	12
461	Characterization of drug-specific lymphocyte responses in a patient with drug-induced liver injury. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 680-683.e5.	1.5	12
462	Activation of carbamazepine-responsive T-cell clones with metabolically inert halogenated derivatives. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 493-495.	1.5	12
463	HLA-DQ allele-restricted activation of nitroso sulfamethoxazole-specific CD4-positive T lymphocytes from patients with cystic fibrosis. <i>Clinical and Experimental Allergy</i> , 2015, 45, 1305-1316.	1.4	12
464	Progress in pharmacogenetics: consortiums and new strategies. <i>Drug Metabolism and Personalized Therapy</i> , 2016, 31, 17-23.	0.3	12
465	Investigating the clinical factors and comedications associated with circulating levels of atorvastatin and its major metabolites in secondary prevention. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 62-74.	1.1	12
466	Anticoagulation in sub-Saharan Africa: Are direct oral anticoagulants the answer? A review of lessons learnt from warfarin. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3699-3705.	1.1	12
467	HLA-DQB1 6672G>C (rs113332494) is associated with clozapine-induced neutropenia and agranulocytosis in individuals of European ancestry. <i>Translational Psychiatry</i> , 2021, 11, 214.	2.4	12
468	HLA Class-II-Restricted CD8+ T Cells Contribute to the Promiscuous Immune Response in Dapsone-Hypersensitive Patients. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2412-2425.e2.	0.3	12

#	ARTICLE	IF	CITATIONS
469	A Review of A Priori Regression Models for Warfarin Maintenance Dose Prediction. PLoS ONE, 2014, 9, e114896.	1.1	12
470	Vitamin D, vitamin D-binding protein, free vitamin D and COVID-19 mortality in hospitalized patients. American Journal of Clinical Nutrition, 2022, 115, 1367-1377.	2.2	12
471	Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine. Archives of Dermatology, 1994, 130, 598-604.	1.7	12
472	Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors. Antiviral Therapy, 2005, 10, 207-13.	0.6	12
473	Pharmacogenomics: Relevance and opportunities for clinical pharmacology. British Journal of Clinical Pharmacology, 2022, 88, 3943-3946.	1.1	12
474	Drug-Specific T Cells in An HIV-Positive Patient with Nevirapine-Induced Hepatitis. Antiviral Therapy, 2006, 11, 393-395.	0.6	12
475	Systemic illness with skin eruption, fever and positive lymphocyte transformation test in a patient on irbesartan. British Journal of Dermatology, 2006, 155, 491-493.	1.4	11
476	Release of intracellular calcium primes chronic myeloid leukaemia cells for tyrosine kinase inhibitor-induced apoptosis. Leukemia, 2012, 26, 490-498.	3.3	11
477	Electronic health records for biological sample collection: feasibility study of statin-induced myopathy using the Clinical Practice Research Datalink. British Journal of Clinical Pharmacology, 2014, 77, 831-838.	1.1	11
478	A comparison of HMGB1 concentrations between cerebrospinal fluid and blood in patients with neurological disease. Biomarkers, 2016, 22, 1-8.	0.9	11
479	HLA-A 31:01 is not associated with the development of methotrexate pneumonitis in the UK population: results from a genome-wide association study. Annals of the Rheumatic Diseases, 2017, 76, e51-e51.	0.5	11
480	Open letter on access to the BIA 10-2474 clinical trial data. Lancet, The, 2017, 389, 156.	6.3	11
481	Genetic and nongenetic factors that may predispose individuals to allergic drug reactions. Current Opinion in Allergy and Clinical Immunology, 2018, 18, 325-332.	1.1	11
482	The longitudinal NIHR ARC North West Coast Household Health Survey: exploring health inequalities in disadvantaged communities. BMC Public Health, 2020, 20, 1257.	1.2	11
483	Evaluation of clinical and genetic factors in the population pharmacokinetics of carbamazepine. British Journal of Clinical Pharmacology, 2021, 87, 2572-2588.	1.1	11
484	Combined analysis of transcriptomic and genetic data for the identification of loci involved in glucocorticosteroid response in asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1238-1243.	2.7	11
485	Probenecid Increases the Concentration of 7-Chlorokynurenic Acid Derived from the Prodrug 4-Chlorokynurenine within the Prefrontal Cortex. Molecular Pharmaceutics, 2021, 18, 113-123.	2.3	11
486	Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsy. Journal of Clinical Investigation, 2019, 129, 2166-2166.	3.9	11

#	ARTICLE	IF	CITATIONS
487	Risperidone-induced photosensitivity.. Postgraduate Medical Journal, 1998, 74, 252-253.	0.9	10
488	Haemolytic anaemia associated with indinavir. Postgraduate Medical Journal, 1999, 75, 313-315.	0.9	10
489	The adverse effects of drugs. British Journal of Hospital Medicine, 1999, 60, 348-352.	0.3	10
490	An Investigation of Disagreement in Causality Assessment of Adverse Drug Reactions. Pharmaceutical Medicine, 2011, 25, 17-24.	1.0	10
491	A randomised controlled trial of extended brief intervention for alcohol dependent patients in an acute hospital setting (ADPAC). BMC Public Health, 2011, 11, 528.	1.2	10
492	Treatment of paracetamol overdose: room for improvement?. Lancet, The, 2014, 383, 672-674.	6.3	10
493	A pilot randomised controlled trial to assess the utility of an e-learning package that trains users in adverse drug reaction causality. International Journal of Pharmacy Practice, 2015, 23, 447-455.	0.3	10
494	Variation in warfarin prescribing and dosing in the UK: a national survey of anticoagulation clinics. Journal of Clinical Pharmacy and Therapeutics, 2015, 40, 466-471.	0.7	10
495	Hemolytic anemia in two patients with glioblastoma multiforme: A possible interaction between vorinostat and dapson. Journal of Oncology Pharmacy Practice, 2015, 21, 220-223.	0.5	10
496	Epidemiology of alcohol dependence in UK primary care: Results from a large observational study using the Clinical Practice Research Datalink. PLoS ONE, 2017, 12, e0174818.	1.1	10
497	TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral Therapy. Clinical Infectious Diseases, 2020, 70, 2062-2072.	2.9	10
498	Pharmacogenomic associations of adverse drug reactions in asthma: systematic review and research prioritisation. Pharmacogenomics Journal, 2020, 20, 621-628.	0.9	10
499	Associations between occupation and heavy alcohol consumption in UK adults aged 40-69 years: a cross-sectional study using the UK Biobank. BMC Public Health, 2021, 21, 190.	1.2	10
500	T cell mediated hypersensitivity to previously tolerated iodinated contrast media precipitated by introduction of atezolizumab. , 2021, 9, e002521.		10
501	Factors Affecting Patient and Physician Engagement in Remote Health Care for Heart Failure: Systematic Review. JMIR Cardio, 2022, 6, e33366.	0.7	10
502	A reference set of clinically relevant adverse drug-drug interactions. Scientific Data, 2022, 9, 72.	2.4	10
503	Stable warfarin dose prediction in sub-Saharan African patients: A machine learning approach and external validation of a clinical dose initiation algorithm. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 20-29.	1.3	10
504	Research Highlights: Explanation for <i>HLA-B*57:01</i>-linked immune-mediated abacavir-induced hypersensitivity. Pharmacogenomics, 2012, 13, 1567-1569.	0.6	9

#	ARTICLE	IF	CITATIONS
505	Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral therapy. <i>BMJ Open</i> , 2015, 5, e009566.	0.8	9
506	Repurposing Statins for Renal Protection: Is It a Class Effect?. <i>Clinical and Translational Science</i> , 2018, 11, 100-102.	1.5	9
507	Characterization of Clozapine-Responsive Human T Cells. <i>Journal of Immunology</i> , 2020, 205, 2375-2390.	0.4	9
508	Deciphering Adverse Drug Reactions: <i>In Vitro</i> Priming and Characterization of Vancomycin-Specific T Cells From Healthy Donors Expressing HLA-A*32:01. <i>Toxicological Sciences</i> , 2021, 183, 139-153.	1.4	9
509	Adverse drug reactions as cause of admission to hospital: Authors' reply. <i>BMJ: British Medical Journal</i> , 2004, 329, 460.2.	2.4	9
510	Hepatitis B vaccine and neurotoxicity.. <i>Postgraduate Medical Journal</i> , 1997, 73, 462-463.	0.9	8
511	Anticipating, investigating and managing the adverse effects of drugs. <i>Clinical Medicine</i> , 2005, 5, 23-26.	0.8	8
512	Genetic variants of hepatic transporters and susceptibility to drug induced liver injury. <i>Toxicology</i> , 2008, 253, 10.	2.0	8
513	Clinical management of HIV-associated lipodystrophy. <i>Current Opinion in Lipidology</i> , 2009, 20, 309-314.	1.2	8
514	The accumulation and metabolism of zidovudine in 3T3-L1 adipocytes. <i>British Journal of Pharmacology</i> , 2010, 159, 484-493.	2.7	8
515	Development of predictive genetic tests for improving the safety of new medicines: the utilization of routinely collected electronic health records. <i>Drug Discovery Today</i> , 2014, 19, 361-366.	3.2	8
516	Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 465-472.	1.9	8
517	Telmisartan reverses antiretroviral-induced adipocyte toxicity and insulin resistance <i>in vitro</i> . <i>Diabetes and Vascular Disease Research</i> , 2018, 15, 233-242.	0.9	8
518	Developing and Validating a Clinical Warfarin Dose-Initiation Model for Black African Patients in South Africa and Uganda. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1564-1574.	2.3	8
519	The Interface of Therapeutics and Genomics in Cardiovascular Medicine. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 663-676.	1.3	8
520	HLA Allele-Restricted Immune-Mediated Adverse Drug Reactions: Framework for Genetic Prediction. <i>Annual Review of Pharmacology and Toxicology</i> , 2022, 62, .	4.2	8
521	3 The pharmacology of the cytochrome P450 enzyme system. <i>Bailliere's Clinical Anaesthesiology</i> , 1998, 12, 191-211.	0.2	7
522	The applications of pharmacogenetics to prescribing: what is currently practicable?. <i>Clinical Medicine</i> , 2009, 9, 493-495.	0.8	7

#	ARTICLE	IF	CITATIONS
523	Deletion of exon 3 in the growth hormone receptor gene in adults with growth hormone deficiency: comparison of symptomatic and asymptomatic patients. <i>Clinical Endocrinology</i> , 2010, 72, 422-423.	1.2	7
524	Adipogenic gene variants in patients with HIV-associated lipodystrophy. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 76-83.	0.7	7
525	Immunomodulatory interventions for focal epilepsy syndromes. <i>The Cochrane Library</i> , 2013, , CD009945.	1.5	7
526	Pharmacotherapy for alcohol dependence: A stratified approach. , 2015, 153, 10-24.		7
527	Genetic testing for prevention of severe drug-induced skin rash. <i>The Cochrane Library</i> , 2019, 7, CD010891.	1.5	7
528	Cardiovascular drugs and COVID-19 clinical outcomes: a systematic review and meta-analysis of randomized controlled trials. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3577-3599.	1.1	7
529	Similarity and consistency assessment of three major online drug-drug interaction resources. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 4067-4079.	1.1	7
530	Interpreting adverse drug reaction (ADR) reports as hospital patient safety incidents. <i>British Journal of Clinical Pharmacology</i> , 2010, 70, 102-108.	1.1	6
531	Genetic testing for prevention of severe drug-induced skin rash. <i>The Cochrane Library</i> , 2013, , .	1.5	6
532	Is the Interleukin 8 Promoter Polymorphism rs4073/-251T &gt;A Associated With Clostridium difficile Infection?. <i>Clinical Infectious Diseases</i> , 2014, 58, e148-e151.	2.9	6
533	Copy number variation in exportin-4 (XPO4) gene and its association with histological severity of non-alcoholic fatty liver disease. <i>Scientific Reports</i> , 2015, 5, 13306.	1.6	6
534	Trastuzumab uptake in HER2-positive breast cancer patients: a systematic review and meta-analysis of observational studies. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 130, 92-107.	2.0	6
535	Trends in BRCA testing and socioeconomic deprivation. <i>European Journal of Human Genetics</i> , 2019, 27, 1351-1360.	1.4	6
536	Nonmedical prescriber experiences of training and competence to report adverse drug reactions in the UK. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2019, 44, 78-83.	0.7	6
537	Identification of ROBO2 as a Potential Locus Associated with Inhaled Corticosteroid Response in Childhood Asthma. <i>Journal of Personalized Medicine</i> , 2021, 11, 733.	1.1	6
538	Pharmacogenomics of Drug Hypersensitivity. <i>Immunology and Allergy Clinics of North America</i> , 2022, 42, 335-355.	0.7	6
539	Lipodystrophy in Patients with HIV-1 Infection: Effect of Stopping Protease Inhibitors on Tnf- $\alpha$ and Tnf-Receptor Levels, and on Metabolic Parameters. <i>Antiviral Therapy</i> , 2004, 9, 879-887.	0.6	6
540	Drug hypersensitivity reactions in patients with HIV disease. <i>Expert Review of Clinical Immunology</i> , 2007, 3, 395-410.	1.3	5

#	ARTICLE	IF	CITATIONS
541	Prescribing in liver disease. <i>Medicine</i> , 2007, 35, 31-34.	0.2	5
542	Drug metabolism. <i>Medicine</i> , 2008, 36, 355-359.	0.2	5
543	A comprehensive functional and clinical analysis of ABCC2 and its impact on treatment response to carbamazepine. <i>Pharmacogenomics Journal</i> , 2014, 14, 481-487.	0.9	5
544	Covalent adduction of carbamazepine 10, 11-epoxide with human serum albumin and glutathione S-transferase pi: implications for carbamazepine hypersensitivity. <i>Lancet, The</i> , 2014, 383, S114.	6.3	5
545	P1112 : Baclofen: Maintenance of abstinence in alcohol dependent patients attending liver clinic. <i>Journal of Hepatology</i> , 2015, 62, S767.	1.8	5
546	Pharmacogenetics and Pharmacogenomics. , 2016, , 121-137.		5
547	CKMGl <sub>u</sub> 83Gly Is Associated With Blunted Creatine Kinase Variation, but Not With Myalgia. <i>Circulation: Cardiovascular Genetics</i> , 2017, 10, .	5.1	5
548	HLA- and immune-mediated adverse drug reactions: Another hit with vancomycin. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 44-45.	1.5	5
549	Genome-Wide association between EYA1 and Aspirin-induced peptic ulceration. <i>EBioMedicine</i> , 2021, 74, 103728.	2.7	5
550	UK veterinary professionals' perceptions and experiences of adverse drug reaction reporting. <i>Veterinary Record</i> , 2022, 191, .	0.2	5
551	LACK OF INTERACTION BETWEEN SULPHASALAZINE AND CIMETIDINE IN PATIENTS WITH RHEUMATOID ARTHRITIS. <i>Rheumatology</i> , 1993, 32, 222-226.	0.9	4
552	Commentary--bisphosphonates and calcium homeostasis. <i>Postgraduate Medical Journal</i> , 2000, 76, 418-419.	0.9	4
553	Drug presentation to T cells. <i>Journal of Allergy and Clinical Immunology</i> , 2005, 115, 876-877.	1.5	4
554	Trimethoprim Stimulates T-Cells through Metabolism-Dependent and -Independent Pathways. <i>Chemical Research in Toxicology</i> , 2011, 24, 791-793.	1.7	4
555	Anticonvulsant Agents. , 2013, , 423-441.		4
556	RXR $\beta$ gene variants are associated with HIV lipodystrophy. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 438-441.	0.7	4
557	Clinical coding of prospectively identified paediatric adverse drug reactions " a retrospective review of patient records. <i>BMC Pharmacology &amp; Toxicology</i> , 2014, 15, 72.	1.0	4
558	Quantification of urinary mevalonic acid as a biomarker of HMG-CoA reductase activity by a novel translational LC-MS/MS method. <i>Bioanalysis</i> , 2014, 6, 919-933.	0.6	4



#	ARTICLE	IF	CITATIONS
559	An integrative <i>in silico</i> system for predicting dysregulated genes in the human epileptic focus: Application to SLC transporters. <i>Epilepsia</i> , 2016, 57, 1467-1474.	2.6	4
560	Age-stratified outcome of a genotype-guided dosing algorithm for acenocoumarol and phenprocoumon. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 454-464.	1.9	4
561	TEMPORARY REMOVAL: Reference intervals for putative biomarkers of drug-induced liver injury and liver regeneration in healthy human volunteers. <i>Journal of Hepatology</i> , 2018, , .	1.8	4
562	Processes and barriers to implementation of point-of-care genotype-guided dosing of warfarin into UK outpatient anticoagulation clinics. <i>Pharmacogenomics</i> , 2019, 20, 599-608.	0.6	4
563	A randomised controlled trial of rosuvastatin for the prevention of aminoglycoside-induced kidney toxicity in children with cystic fibrosis. <i>Scientific Reports</i> , 2020, 10, 1796.	1.6	4
564	Alcohol abuse and the burden on the NHS--time for action. <i>Journal of the Royal College of Physicians of London</i> , 2000, 34, 161-2.	0.2	4
565	Effectiveness of the Med Safety mobile application in improving adverse drug reaction reporting by healthcare professionals in Uganda: a protocol for a pragmatic cluster-randomised controlled trial. <i>BMJ Open</i> , 2022, 12, e061725.	0.8	4
566	Polymorphism in gene for microsomal epoxide hydrolase and lung disease. <i>Lancet</i> , The, 1997, 350, 1553.	6.3	3
567	Drug metabolism and drug toxicity. <i>Inflammopharmacology</i> , 2001, 9, 183-199.	1.9	3
568	Editorial Commentary: Statins, Immunomodulation, and Infections: A Complex and Unresolved Relationship. <i>Clinical Infectious Diseases</i> , 2014, 58, 357-358.	2.9	3
569	66 Association of urinary kidney injury molecule-1 with aminoglycoside exposure in children with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2014, 13, S63.	0.3	3
570	Prescribing in liver disease. <i>Medicine</i> , 2015, 43, 577-580.	0.2	3
571	A Randomized Controlled Trial of Extended Brief Intervention for Alcohol-Dependent Patients in an Acute Hospital Setting. <i>Alcohol and Alcoholism</i> , 2016, 51, 584-592.	0.9	3
572	Working together to deliver stratified medicine research effectively. <i>British Medical Bulletin</i> , 2019, 129, 107-116.	2.7	3
573	Chapter 5. Drug Transporters at the Blood-Brain Barrier. , 0, , 151-183.		3
574	Mechanisms of Hypertransaminemia. <i>Handbook of Experimental Pharmacology</i> , 1996, , 411-440.	0.9	3
575	No association between tacrine transaminitis and the glutathione transferase theta genotype in patients with Alzheimer's disease. <i>Pharmacogenetics and Genomics</i> , 1998, 8, 353-5.	5.7	3
576	Reporting of adverse drug reactions: practice in the UK. <i>Nursing Times</i> , 1998, 94, 52-4.	0.2	3

#	ARTICLE	IF	CITATIONS
577	Drug-specific T cells in an HIV-positive patient with nevirapine-induced hepatitis. <i>Antiviral Therapy</i> , 2006, 11, 393-5.	0.6	3
578	Mechanisms of Adverse Drug Reactions. , 0, , 85-103.		3
579	Adverse drug reactions as a cause of admission to an acute medical assessment unit: a pilot study. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2000, 25, 355-361.	0.7	2
580	Urinary KIM-1 as a Biomarker of Aminoglycoside-Induced Nephrotoxicity in Premature Neonates. <i>Pediatric Research</i> , 2011, 70, 107-107.	1.1	2
581	S31â€¦Variation at GLCC1: Association with Increased Steroid Dose But Not Adrenal Suppression in Asthmatic Children. <i>Thorax</i> , 2012, 67, A17.2-A17.	2.7	2
582	Identification of susceptible HLA class II coâ€¦amoxiclav genotypes based on the analysis of drugâ€¦specific Tâ€¦cells from patients with liver injury. <i>Clinical and Translational Allergy</i> , 2014, 4, O3.	1.4	2
583	Pharmacogenetics for the prescriber. <i>Medicine</i> , 2016, 44, 412-415.	0.2	2
584	Genetic Predisposition to Anticonvulsant Hypersensitivity. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 919-922.	2.3	2
585	Evidence to Support Inclusion of Pharmacogenetic Biomarkers in Randomised Controlled Trials. <i>Journal of Personalized Medicine</i> , 2019, 9, 42.	1.1	2
586	Precision medicine in drug safety. <i>Current Opinion in Toxicology</i> , 2020, 23-24, 87-97.	2.6	2
587	Assessing the impact of alcohol consumption on the genetic contribution to mean corpuscular volume. <i>Human Molecular Genetics</i> , 2021, 30, 2040-2051.	1.4	2
588	Examining the uptake of predictive BRCA testing in the UK; findings and implications. <i>European Journal of Human Genetics</i> , 2021, 29, 699-708.	1.4	2
589	Hydralazine-induced lupus: yet another autoantibody!. <i>Human and Experimental Toxicology</i> , 1996, 15, 361-362.	1.1	1
590	A simple sore throat?. <i>British Journal of Hospital Medicine</i> , 2000, 61, 435-435.	0.3	1
591	Best evidence and the clinical decision making process. <i>Postgraduate Medical Journal</i> , 2002, 78, 316-316.	0.9	1
592	Understanding drug interactions. <i>Nursing and Residential Care</i> , 2002, 4, 312-317.	0.1	1
593	The BPS web site for Continuing Professional Development in Clinical Pharmacology and Therapeutics. <i>British Journal of Clinical Pharmacology</i> , 2003, 56, 349-350.	1.1	1
594	HIV and Drug Hypersensitivity. , 2007, , 84-94.		1

#	ARTICLE	IF	CITATIONS
595	Prescribing in liver disease. <i>Medicine</i> , 2011, 39, 541-544.	0.2	1
596	Risk modeling strategies for pharmacogenetic studies. <i>Pharmacogenomics</i> , 2011, 12, 397-410.	0.6	1
597	General pharmacology. , 2012, , 74-109.		1
598	Response 2 to pharmacogenetic screening to prevent carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome: a critical appraisal. <i>British Journal of Dermatology</i> , 2012, 166, 12-14.	1.4	1
599	Cost Effectiveness of Pharmacogenetic Screening Prior to Initiation of Carbamazepine Treatment for Epilepsy. <i>Value in Health</i> , 2013, 16, A624.	0.1	1
600	Response to "HLA Allelic Variants and Carbamazepine-Induced Hypersensitivity": <i>Clinical Pharmacology and Therapeutics</i> , 2013, 93, 387-387.	2.3	1
601	Pharmacogenetics in the treatment of chronic lymphocytic leukemia: what does the future hold?. <i>Pharmacogenomics</i> , 2014, 15, 897-900.	0.6	1
602	Personalized Medicine in Cardiovascular Disease. , 2017, , 457-471.		1
603	Adrenal suppression with inhaled corticosteroids: the seed and the soil " Authors' reply. <i>Lancet Respiratory Medicine</i> , 2018, 6, e20.	5.2	1
604	REPLICATION OF TWO INDEPENDENT LOCI IN HLA-DQB1 AND HLA-B CONTRIBUTING TO THE RISK OF CLOZAPINE-INDUCED AGRANULOCYTOSIS. <i>European Neuropsychopharmacology</i> , 2019, 29, S939.	0.3	1
605	Plasma Methylmalonic Acid Concentration in Folic Acid"Supplemented Depressed Patients with Low or Marginal Vitamin B-12: A Randomized Trial. <i>Journal of Nutrition</i> , 2021, 151, 3738-3745.	1.3	1
606	Metabolic Models of Cytotoxicity. , 1999, , 443-476.		1
607	Unlike Imatinib, Dasatinib Uptake into Chronic Myeloid Leukaemia Cells Is Independent of hOCT1 Expression.. <i>Blood</i> , 2007, 110, 3458-3458.	0.6	1
608	Prescribing in epilepsy. <i>Practitioner</i> , 1990, 234, 1070-2.	0.3	1
609	Chromosomal Region 11p14.1 is Associated with Pharmacokinetics and Pharmacodynamics of Bisoprolol. <i>Pharmacogenomics and Personalized Medicine</i> , 2022, Volume 15, 249-260.	0.4	1
610	Antiprotozoal drugs. <i>Side Effects of Drugs Annual</i> , 1993, , 325-336.	0.6	0
611	Antiprotozoal drugs. <i>Side Effects of Drugs Annual</i> , 1994, 18, 286-298.	0.6	0
612	Antiprotozoal drugs. <i>Side Effects of Drugs Annual</i> , 1995, , 262-272.	0.6	0

#	ARTICLE	IF	CITATIONS
613	Glutathione Deficiency in Hiv-Infected Patients: A True or Technical Deficiency?. <i>Clinical Science</i> , 1996, 91, 9P-9P.	0.0	0
614	Chapter 37 Idiosyncratic drug reactions. <i>Principles of Medical Biology</i> , 1997, , 737-761.	0.1	0
615	Antiprotozoal drugs. <i>Side Effects of Drugs Annual</i> , 1997, 20, 257-268.	0.6	0
616	Investigation of Tumour Necrosis Factor Receptor Polymorphisms in Alcoholic Liver Disease. <i>Clinical Science</i> , 1999, 97, 8P-9P.	0.0	0
617	Effect of Carbamazepine on TNF- $\alpha$ Expression: Comparison of Carbamazepine Hypersensitive and Non-Hypersensitive Patients. <i>Clinical Science</i> , 1999, 97, 9P-9P.	0.0	0
618	Optimal dose identification: predicting a safe dose in man from animal studies. <i>International Congress Series</i> , 2001, 1220, 13-25.	0.2	0
619	Genetic determinants of dose optimisation: molecular biology in the prevention of drug toxicity. <i>International Congress Series</i> , 2001, 1220, 187-202.	0.2	0
620	PIN11 ABACAVIR HYPERSENSITIVITY: IS PREPRESCRIPTION GENOTYPING COSTEFFECTIVE?. <i>Value in Health</i> , 2003, 6, 749.	0.1	0
621	PM2 IMPACT OF PHARMACOGENETICS ON THE COSTS OF MANAGING ADVERSE EVENTS WITH WARFARIN: A PROSPECTIVE ANALYSIS. <i>Value in Health</i> , 2009, 12, A3-A4.	0.1	0
622	Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-1 infected patients from Malawi. <i>Journal of the International AIDS Society</i> , 2010, 13, P181.	1.2	0
623	Authors' reply to Zermansky and Khatib. <i>BMJ: British Medical Journal</i> , 2011, 343, d7718-d7718.	2.4	0
624	Changing trends in peptic ulcer disease: the rise of NSAID-induced and fall of H pylori-induced ulcers. <i>Gut</i> , 2011, 60, A104-A105.	6.1	0
625	052...Exploring the genetic basis of pharmacoresistance in epilepsy: an integrative analysis of large-scale gene expression profiling studies on brain tissue from epilepsy surgery. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, e1.218-e1.	0.9	0
626	PWE-165...CYP2C19*17 gain of function mutation is associated with peptic ulcer disease. <i>Gut</i> , 2012, 61, A363.1-A363.	6.1	0
627	Letter: are idiopathic (non-NSAID, non-Helicobacter pylori) ulcers really increasing? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 601-602.	1.9	0
628	Pharmacogenetics for the prescriber. <i>Medicine</i> , 2012, 40, 362-365.	0.2	0
629	Commentary: changing aetiology of peptic ulcers - author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 292-293.	1.9	0
630	Institutional Profile: The Wolfson Centre for Personalised Medicine, University of Liverpool, Liverpool, UK. <i>Pharmacogenomics</i> , 2013, 14, 861-867.	0.6	0

#	ARTICLE	IF	CITATIONS
631	Stroke Pharmacogenetics. , 2013, , 223-297.		0
632	Author's reply to Backman and Bakhai. BMJ, The, 2013, 346, f1078-f1078.	3.0	0
633	WHICH GENETIC PATHWAYS UNDERLIE PHARMACORESISTANT EPILEPSY?. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, e4.172-e4.	0.9	0
634	PO-0926â€¦Are Group Assessments Superior To Individual Avoidability Assessments? A Test Of The Liverpool Adverse Drug Reaction Avoidability Assessment Tool. Archives of Disease in Childhood, 2014, 99, A552.3-A553.	1.0	0
635	Characterization of amoxicillin and clavulanicâ€¦acidâ€¦responsive CD4+ And CD8+ Tâ€¦cells in patients with coâ€¦amoxiclavâ€¦induced liver injury. Clinical and Translational Allergy, 2014, 4, P42.	1.4	0
636	HLAâ€¦DQ restricted activation of nitrosoâ€¦sulfamethoxazoleâ€¦specific CD4+ Tâ€¦lymphocytes. Clinical and Translational Allergy, 2014, 4, P110.	1.4	0
637	Establishment of an HLAâ€¦typed cohort of 1000 healthy blood donors and use of a dendritic cell priming assay to prime naive T cells to structurally divergent drugs. Clinical and Translational Allergy, 2014, 4, P112.	1.4	0
638	Skewing of the TCR V repertoire in SMXâ€¦NO specific T cell responses. Clinical and Translational Allergy, 2014, 4, P114.	1.4	0
639	Antigen exposure required for T cell activation. Clinical and Translational Allergy, 2014, 4, P115.	1.4	0
640	Abs No: HLAâ€¦A*31:01 positive hypersensitive patient. Clinical and Translational Allergy, 2014, 4, P117.	1.4	0
641	Genomeâ€¦wide association study of nevirapine hypersensitivity in a malawian HIVâ€¦infected population. Clinical and Translational Allergy, 2014, 4, P125.	1.4	0
642	CYP2B6*18 is associated with nevirapine hypersensitivity independently of HLAâ€¦C*04:01Î±in a Malawian HIV population. Clinical and Translational Allergy, 2014, 4, P126.	1.4	0
643	PO-0925â€¦Children And Young Peopleâ€¦TM's Experiences Of Adverse Drug Reactions And Pharmacovigilance In The Uk. Archives of Disease in Childhood, 2014, 99, A552.2-A552.	1.0	0
644	PTU-118â€¦Baclofen As An Adjunct Pharmacotherapy For The Maintenance Of Abstinence In Alcohol Dependent Patients With Liver Disease. Gut, 2014, 63, A90.3-A91.	6.1	0
645	Health-Economic Evaluation of Clostridium Difficile Infection (Cdi) And Epidemiology In England And Merseyside. Value in Health, 2015, 18, A582.	0.1	0
646	A candidate gene study for oxaliplatin induced chronic peripheral neuropathy (OICPN) based on a prior genome wide association study (GWAS). Annals of Oncology, 2016, 27, vi543.	0.6	0
647	PAEDIATRIC ADVERSE DRUG REACTIONS (ADRS): A COMPARISON OF A NEWLY DEVELOPED AVOIDABILITY TOOL TO EXISTING HALLAS ASSESSMENTS. Archives of Disease in Childhood, 2016, 101, e2.70-e2.	1.0	0
648	Examination Of Equity In The Delivery Of Personalised Medicines. Value in Health, 2016, 19, A266.	0.1	0

#	ARTICLE	IF	CITATIONS
649	Assessment of gene expression profiles of peripheral blood mononuclear cells from patients with a history of carbamazepine hypersensitivity. <i>Lancet, The</i> , 2017, 389, S104.	6.3	0
650	Letter to the Editor: Response to Costa et al.. <i>European Neuropsychopharmacology</i> , 2018, 28, 658.	0.3	0
651	Nucleic acid based therapies: developing frontier for precision medicine. <i>BMJ: British Medical Journal</i> , 2018, 360, k223.	2.4	0
652	Pharmacogenetics and Pharmacogenomics in Cardiovascular Medicine and Surgery. , 2018, , 119-172.		0
653	The unexpected challenges of immunotherapy. <i>Annals of Oncology</i> , 2018, 29, x20.	0.6	0
654	9â€¦Applying personalised medicine in clinical practice. , 2018, , .		0
655	OWE-019â€¦Mechanisms of chemotherapy-induced diarrhoea. , 2018, , .		0
656	Trastuzumab Uptake In HER2-Positive Breast Cancer Patients: A Systematic Review And Meta-Analysis Of Observational Studies. <i>Value in Health</i> , 2018, 21, S43.	0.1	0
657	P45â€¦The acceptability of using genetic information to guide treatment of asthma to children, young people, and parents (pilot study). <i>Archives of Disease in Childhood</i> , 2019, 104, e35.3-e36.	1.0	0
658	Pharmacogenetics for the prescriber. <i>Medicine</i> , 2020, 48, 439-442.	0.2	0
659	Inflammatory Bowel Disease: A Personalized Approach. <i>Frontiers in Pediatrics</i> , 2020, 8, 620545.	0.9	0
660	TNF-Î± promoter region gene polymorphisms in patients with alcohol-induced chronic pancreatitis. <i>Gastroenterology</i> , 2001, 120, A32-A33.	0.6	0
661	Interleukin-10 promoter region polymorphisms and alcoholic liver disease. <i>Gastroenterology</i> , 2001, 120, A543-A543.	0.6	0
662	Clinical and Functional Evidence That Drug Transporter Expression Dictates the Response to Imatinib in Chronic Myeloid Leukaemia.. <i>Blood</i> , 2006, 108, 2145-2145.	0.6	0
663	Pharmacogenetics of Adverse Drug Reactions. <i>Advances in Predictive, Preventive and Personalised Medicine</i> , 2015, , 109-156.	0.6	0
664	Defining uncontrolled childhood asthma in the global PiCA consortium. , 2016, , .		0
665	Stroke Pharmacogenetics. , 2017, , 327-410.		0
666	Genome-wide association study of inhaled corticosteroid response in African-admixed children with asthma. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
667	Genome-wide association study of asthma exacerbations in European children treated with inhaled corticosteroids. , 2017, , .		0
668	Two distinct clinical trajectories of inflammatory thyroiditis evoked by checkpoint blockade in malignant melanoma.. Journal of Clinical Oncology, 2018, 36, 131-131.	0.8	0
669	Telmisartan to reduce insulin resistance in HIV-positive individuals on combination antiretroviral therapy: the TAILoR dose-ranging Phase II RCT. Efficacy and Mechanism Evaluation, 2019, 6, 1-168.	0.9	0
670	Pharmacogenomics of Anti-Cancer Drugs. , 2021, , .		0